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Abstract 
Despite considerable research efforts, the cellular and molecular mechanisms involved in the 
initiation and progression of Parkinson’s disease (PD) are still unknown. As a consequence, 
no treatment that slows down or stops the progression of the disease is currently available. In 
an effort better to understand the molecular pathogenesis of this disease, we review here the 
biochemical changes that have been documented through the observation and the analysis of 
postmortem PD brains. 
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Introduction 
 
Parkinson disease (PD) is a progressive neurodegenerative illness of the human nervous 
system afflicting more than 1% of people over the age of 65 and more than 4% of the 
population by the age of 85 (de Rijk et al. 2000). The diagnosis of PD depends upon the 
presence of motor deficits that in turn are predominantly the consequence of loss of 
dopaminergic neurons of the substantia nigra (SN). Non-motor symptoms may develop prior 
to motor deficits, but more frequently appear in the more advanced stages and are due to loss 
of both dopaminergic and non-dopaminergic neuronal pathways (Chaudhuri et al. 2006). 
Despite significant research efforts undertaken to understand PD, available treatments are 
only symptomatic and do not affect the progression of the disease. Several reasons have been 
proposed to explain this failure, in particular the fact that research for effective treatments is 
hampered by lack of knowledge on the pathogenetic processes explaining this 
disease(Stanzione and Tropepi 2011). Indeed, while existing cellular and animal models are 
important for our understanding of the apparent pathogenesis of PD, paradigms that reflect the 
progressive nature of the illness and its complexity in terms of the extent of pathology and 
underlying biochemical changes are also lacking. Consequently, the progress in the 
development of approaches that stop or slow the disease progression is very low(Duty and 
Jenner 2011). 
PD is a pathology affecting only humans. For this reason we believe that the study of the 
human brain is a prerequisite for understanding this disorder. Here we review the molecular 
changes observed through the analysis of the human postmortem PD brains. We will address 
here the changes in  protein expression, excluding RNA expression data (reviewed 
elsewhere(Cooper-Knock et al. 2012)) and discuss changes in PD brain only. 
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Neurotransmitters and neurotrophic factors 
Neurotransmitters, receptors and transporters 
Cell loss is observed in PD in several brain areas. While dopaminergic cell loss is believed to 
be responsible for the motor alterations in the disease, glutamatergic, cholinergic, 
tryptaminergic, GABAergic, noradrenergic and adrenergic neurons are also affected during 
the progression of the pathology(Braak and Braak 2000) (Table 1). Levels of tyrosine 
hydroxylase (TH), the rate limiting enzyme in dopamine synthesis, dopamine transporters 
(DAT) and vesicular monoamine transporter 2(Thibaut et al. 1995) (VMAT2) are severely 
reduced in the SN of PD patients(Kastner et al. 1993). In dopaminergic neurons, increased 
levels of neuromelanin were reported, suggesting increased oxidation of dopamine(Halliday et 
al. 2005). Accordingly, the content of the oxidized metabolites of dopamine, notably 5-S-
Cysteinyl-Dopamine, 5-S-Cysteinyl-DOPA and 5-S-Cysteinyl-DOPAC(Spencer et al. 1998) 
as well as NADH quinone oxidoreductase(van Muiswinkel et al. 2004) (NQO1), an enzyme 
that detoxifies dopamine quinone, are also increased.  
The loss of dopaminergic neurons projecting fibers in the striatum induces a strong decrease 
in TH, DAT and VMAT2 levels in the caudate nucleus and the putamen(Wills et al. 2010; 
Miller et al. 1999; Ryoo et al. 1998; Güzey et al. 2012); while dopamine levels and its 
catabolites DOPAC and HVA are severely impaired in caudate nucleus, putamen and nucleus 
accumbens(Gerlach et al. 1996). Nevertheless, dopamine receptor 1(Mattila et al. 2001; 
Piggott et al. 1999; Griffiths et al. 1994) (D1R) and dopamine receptor 3(Piggott et al. 1999) 
(D3R) densities are not affected by the loss of dopaminergic fibers, while its effect on 
dopamine receptor 2 (D2R) is unclear(Varani et al. 2010; Ahlskog et al. 1991; Piggott et al. 
1999; Griffiths et al. 1994). 
The progression of the pathology also severely impacts the cholinergic system. Indeed, 
choline acetyltransferase, which catalyzes acetylcholine (Ach) production, is reduced in 
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several brain areas including the hippocampus, thalamus, sub-thalamic nuclei and frontal 
cortex(Rinne et al. 1989; Xuereb et al. 1990; Gotti et al. 2006; Mattila et al. 2001) with 
simultaneous reduction of the activity of acetylcholine esterase(Xuereb et al. 1990). The 
distribution and content of Ach receptors (AchR) is also changed. Global density of AchR is 
increased in the globus pallidus(Griffiths et al. 1990) and decreased in the striatum(Gotti et al. 
2006) where nicotinic AchR density(Court et al. 2000), more particularly α4-, α6-, β2- and 
β3-subunits(Gotti et al. 2006), is also reduced. Decreased levels of α4- and α7-subunits were 
also observed in cortical regions(Burghaus et al. 2003; Banerjee et al. 2000). For the 
muscarinic receptors, contradictory results were observed in the putamen(Griffiths et al. 1994; 
Ahlskog et al. 1991) while increased density of M2 muscarinic receptor was reported in 
cortical structures(Rinne et al. 1989). 
The GABAergic system is affected in PD with increased and decreased levels reported in the 
striatum and the thalamus, respectively(Gerlach et al. 1996). GABA receptor density is also 
decreased in the SN of PD patients(Lloyd et al. 1977), and GABA A receptor (GABAAR) 
reduced in the striatum(Griffiths et al. 1990). This occurs in parallel with changes in 
glutamatergic system. Whereas glutamate levels are not modified in several brain structures 
implicated in the pathology, levels of the glutamate metabolite glutamine are significantly 
elevated in the thalamus, the globus pallidus and the caudate nucleus(Gerlach et al. 1996). 
Interestingly, density of NMDA receptor(Gerlach et al. 1996) and levels of metabotropic 
glutamate receptor 5 (mGluR5) and its downstream regulator β-arrestin(Price et al. 2010) 
were decreased in the caudate nucleus. Finally, several other systems are also dysregulated in 
PD since abnormal levels and/or densities of adenosine 2A(Villar-Menéndez et al. 2014; 
Varani et al. 2010), angiotensin II(Allen et al. 1992), glycine(de Montis et al. 1982), 
neurotensin(Uhl et al. 1986), somatostatin(Uhl et al. 1986), µ- and κ-opiate(Uhl et al. 1986) 
receptors have been  reported. 
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Neurotrophic factors 
Neurotrophic factors are important in the maintenance of neuronal cell survival. Several 
studies demonstrated dysregulation of these factors in PD (Table 1). Glial cell-derived 
neurotrophic factor (GDNF) levels, the prototypical neurotrophic factor for dopaminergic 
neurons, are decreased in the SN of PD patients(Mogi et al. 2001; Chauhan et al. 2001), as 
well as one of its receptor, Ret(Decressac et al. 2012). Brain-derived neurotrophic factor 
(BDNF), another neurotrophic factor essential for neuronal cell survival, is 
underexpressed(Mogi et al. 1999; Imamura et al. 2005; Parain et al. 1999; Chauhan et al. 
2001). Epidermal growth factor (EGF) and its receptors levels are also modified(Mogi et al. 
1994a; Iwakura et al. 2005; Depboylu et al. 2012). Transforming growth factor α 
(TGFα)(Mogi et al. 1995) and β1 (TGFβ1)(Mogi et al. 1995) levels are increased in PD 
brains, while nerve growth factor (NGF)(Mogi et al. 1999), ciliary neurotrophic factor 
(CNTF)(Chauhan et al. 2001) and basic fibroblast growth factor (bFGF)(Tooyama et al. 
1994) are decreased. Neurotrophin-3, -4(Knott et al. 2002; Chauhan et al. 2001), heparin-
binding EGF-like growth factor (HB-EGF)(Iwakura et al. 2005), and corticotropin releasing 
hormone (CRH)(Hoogendijk et al. 1998) expression is not affected in the pathology. 
 
Lewy bodies and PD linked genes 
Lewy bodies 
Another hallmark of PD is the presence of intracytoplasmic fibrillar aggregates possessing a 
dense core and a peripheral halo forming Lewy bodies. Since excellent reviews detailing their 
composition were published(Wakabayashi et al. 2013), this issue will not be discussed in 
details in this review.  
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Postmortem studies have demonstrated that Lewy pathology progressively and gradually 
involves greater parts of Parkisonian brain. This progressive characteristic had been used to 
classify the pathology in several stages. The first lesions appears in stage 1 in the olfactory 
bulb and the dorsal nucleus of the vagal nerve. In stage 2, lesions progress toward the locus 
coeruleus and the caudal raphe nuclei. The lesions then continue their ascending path to reach 
the amygdala, the pedulopontine nuclei and the pars compacta of the substantia nigra. At 
stage 4, 5 and 6, the lesion continues its progression upward and reaches the mesocortical and 
cortical areas (for more details, see (Braak et al. 2003)).  
This apparent ascending progression of the disease, combined with the observation that 
embryonic neuronal grafts transplanted into PD patients also contained Lewy pathology(Li et 
al. 2008), gave rise to the prion-like hypothesis, which states that PD pathology can be 
propagated to neighbouring cells. α-synuclein, one of the main constituent of Lewy 
bodies(Wakabayashi et al. 2013), represents one candidate that could eventually spread the 
pathology since it has the potency to be released from and uptaken by neurons(Steiner et al. 
2011; Chauhan and Jeans 2015). This phenomenon is of particular interest since α-synuclein 
has been found mutated in some familial forms of PD(Polymeropoulos et al. 1997). 
 
PD-linked genes and their interactome 
Genetic studies have shown that 5-10% of PD patients suffer from a monogenic heritable 
form of the disease. Alterations of their expression has also been linked to idiopathic PD 
(Table 2).  
 
α-synuclein 
α-synuclein is of particular interest in respect with PD for mainly two reasons: as the first 
gene reported to contain specific genetic aberration linked to PD(Polymeropoulos et al. 1997), 
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and as one of the main component of Lewy bodies(Wakabayashi et al. 2013), reflecting its 
propensity to aggregate. Interestingly, the analysis of sporadic PD brains demonstrated that 
both soluble and insoluble α-synuclein levels are abnormally high in several brain 
structures(Wills et al. 2010), and at the intracellular level in mitochondria(Devi et al. 2008). 
According to Desplats(Desplats et al. 2011) et al., this overexpression of α-synuclein in PD 
brain could be the result of hypomethylation. Particularly, they observed that DNA 
methyltransferase 1 (DNMT1), which controls the methylation status of α-synuclein, was 
sequestered into the cytoplasm and thus decreased nuclear levels in PD. 
In the PD brain, increased levels of α-synuclein modified through oxidation(Shamoto-Nagai 
et al. 2007), nitration(Giasson et al. 2000) or cleavage(Dufty et al. 2007) were also observed. 
This increase in cleaved α-synuclein could be the result of increased expression of matrix 
metalloprotease-3 (MMP3)(Choi et al. 2011). Increased levels of α-synuclein phosphorylated 
at S129 were also detected in PD brain(Mahul-Mellier et al. 2014), possibly the consequence 
of decreased levels of the SMG1 phosphatidylinositol 3-kinase related kinase(Henderson-
Smith et al. 2013). Note that G-protein-coupled receptor kinase 5 (GRK5) expression, a 
protein that phosphorylates α-synuclein at S129, remained unchanged in PD brain(Arawaka et 
al. 2006). Finally, in the SN of PD patients, the α-synuclein dimer/monomer ratio is 
increased(Sharon et al. 2003). This observation could be, at least in part, due to increased 
levels of tissue transglutaminase in dopaminergic neurons of the SN of PD 
patients(Wilhelmus et al. 2011b; Citron et al. 2002), which had been shown to catalyze the 
formation of α-synuclein crosslinks(Andringa et al. 2004). 
 
Parkin 
Mutations inducing loss of function of the ubiquitin E3 ligase parkin are the most common 
known cause of young-onset familial PD(Dawson and Dawson 2010). Like α-synuclein, 
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parkin was found in Lewy bodies(Schlossmacher et al. 2002). In sporadic PD brains, while 
total parkin levels remained unchanged(Rubio de la Torre et al. 2009; LaVoie et al. 2005; 
Wills et al. 2010), its aggregated form was increased(LaVoie et al. 2005), explaining the 
observed reduction of its soluble form(Lonskaya et al. 2013). The loss of function due to 
parkin mutations in familial PD is paralleled in sporadic PD by a decrease in parkin 
availability and thus, activity. Since parkin functions as an E3 ubiquitin ligase to promote the 
degradation of its substrates via the proteasome, increased levels of parkin substrates should 
be observed in sporadic PD brain. Consistent with this hypothesis, the parkin substrates 
aminoacyl-tRNA synthetase-interacting multifunctional protein type 2(Imam et al. 2011; Ko 
et al. 2010) (AIMP2), also called Jtv1, far upstream element-binding protein-1(Imam et al. 
2011; Ko et al. 2010) (FBP-1), parkin interacting substrate(Shin et al. 2011) (PARIS), 
programmed cell death-2 isoform 1(Fukae et al. 2009) (PDCD2-1) and striatal-enriched 
protein tyrosine phosphatase 61 (STEP61(Kurup et al. 2015)) were all found to accumulate in 
the SN or the striatum of PD brain. Of interest, increased levels of S-nitrosylated 
parkin(Sunico et al. 2013; Chung et al. 2004) were also observed in parkinsonian brain, a 
modification thought to decrease its E3 ubiquitin ligase activity(Chung et al. 2004). 
Moreover, increased phosphorylated parkin levels were also observed(Ko et al. 2006; Imam 
et al. 2011; Rubio de la Torre et al. 2009). This observation is of importance since 
phosphorylation inactivates parkin ubiquitin ligase function. According to several 
studies(Mahul-Mellier et al. 2014; Imam et al. 2011; Ko et al. 2006), this increased 
phosphorylation status would be the consequence of the increased level and activity of the 
non-receptor tyrosine kinase c-Abl. Finally, the parkin interactor nucleus accumbens 1 
(NAC1) aggregated with parkin in dopaminergic neuron of the SN of PD patients(Korutla et 
al. 2014). 
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Other proteins associated with familial PD 
Other proteins found associated with familial PD also presented abnormalities in the 
idiopathic form of the disease. PTEN-induced putative kinase 1(Muqit et al. 2006) (PINK1) 
and leucine-rich repeat kinase 2(Cho et al. 2013; Guerreiro et al. 2013) (LRRK2) levels are 
increased in the brain of PD patients, while ubiquitin C-terminal hydrolase-1 (UCHL-1) levels 
were found reduced in the SN(Barrachina et al. 2006). Interestingly, oxidized levels of DJ-1, 
which is considered as an oxidative stress sensor, are elevated in PD dopaminergic 
neurons(Choi et al. 2014). Of interest, levels and distribution of vacuolar protein sorting 35 
homolog (VPS35), a component of retromer, remained unchanged in PD brain(Tsika et al. 
2014).  
 
Transition metals, calcium and calcium-binding proteins 
Transition metals 
Several studies indicate that metal homeostasis, particularly iron, is disrupted in PD (Table 3). 
Indeed, reports using different technologies indicated that iron levels are significantly 
increased in the SN of PD patients(Dexter et al. 1989; Ayton et al. 2013; Hirsch et al. 1991) 
and in the dopaminergic neurons populating this brain area(Oakley et al. 2007; Jellinger et al. 
1992; Good et al. 1992), more precisely Fe3+ ion levels(Riederer et al. 1989). Increased iron 
has been linked to other pathogenetically relevant features of PD including oxidative stress 
and mitochondrial function(Mann et al. 1994). Moreover, several proteins that bind to or 
transport iron are also deregulated: the expression of such iron transport machinery like 
divalent metal transporter 1(Salazar et al. 2008) (DMT1), transferrin(Mastroberardino et al. 
2009), Nedd4 family interacting protein 1(Howitt et al. 2014) (NDFIP1), a protein implicated 
in the posttranslational control of DMT1, the iron export protein ferroportin(Visanji et al. 
11 
 
2013), as well as the iron-binding proteins ferritin(Riederer et al. 1989), lactoferrin(Rousseau 
et al. 2013; Leveugle et al. 1996) and its receptor(Faucheux et al. 1995) are all increased in 
the SN of PD patients. Interestingly, ceruloplasmin, a protein acting as an iron-export 
ferroxidase, showed a decreased activity in the SN(Howitt et al. 2014). 
Iron is not the only metal found dysregulated in PD. Total copper content is also decreased in 
the SN of PD patients(Dexter et al. 1989; Ayton et al. 2013), as well as the copper transporter 
1 (CTR1). Interestingly, metallothioneins, proteins controlling the bioavailability of metals, 
including copper, were found to be overexpressed in the SN of PD patients. Aluminium and 
zinc content are increased in the SN of PD patients(Good et al. 1992; Hirsch et al. 1991), 
while manganese content is reduced in their putamen(Dexter et al. 1989). 
 
Calcium and calcium-binding proteins 
Calcium appears to be crucial for dopaminergic neuron survival since those of the SNpc 
expressing calbindin D-28K are less susceptible to degenerate in PD(Yamada et al. 1990). 
While total Ca2+ levels remain normal in PD (Table 3), voltage-gated Ca2+ channel (CaV) 1.2 
and 1.3 levels are reduced in the SN of PD patients(Hurley et al. 2013) but not in their 
striatum(Watson et al. 1988). Parvalbumin levels, a protein expressed as a defensive response 
against Ca2+ stress, were also increased(Soós et al. 2004). There are conflicting reports on 
calcium binding proteins calbindin, calmodulin and calreticulin(Reynolds et al. 2008; Hurley 
et al. 2013; Wilhelmus et al. 2011b) while Ca2+-dependent protein kinase (PKC) levels are 
decreased(Tanaka et al. 1993). The calcium dependent-protease calpain II is expressed by a 
larger number of neurons in the SN of PD patients(Mouatt-Prigent et al. 1996), contrary to its 
inhibitor calpastatin(Mouatt-Prigent et al. 2000). Finally, lipocortin-1, a Ca2+-binding protein 
that buffers intracellular calcium involved in microglial activation, was reported to be 
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expressed by microglial cells, suggesting an ongoing inflammatory response(Knott et al. 
2000). 
 
Inflammation 
While the central nervous system (CNS) is considered to be a relatively immune-privileged 
tissue, it is still able to initiate an immune response. This immune response is mediated by 
glial cells, usually initiated by microglial cells, the resident tissue macrophages of the CNS, 
and then amplified by astrocytes(Halliday and Stevens 2011). To maintain proper tissue 
homeostasis and to avoid collateral tissue damage during inflammatory reactions, all of the 
inflammatory responses must eventually be terminated. However, several studies indicate that 
an inflammatory response is ongoing in the parkinsonian brain (Table 4).  
In PD brains, the number of microglial cells is increased(Lastres-Becker et al. 2012; Imamura 
et al. 2003) in comparison to control brains. Moreover, these cells are activated since the 
number of microglial cells expressing activation markers like HLA-DR(Orr et al. 2005; 
Imamura et al. 2003; Imamura et al. 2005), ICAM-1(Imamura et al. 2003), CD68(Vroon et 
al. 2007), lymphocyte function-associated antigen 1(Miklossy et al. 2006) (LFA-1), activated 
caspase-3/8(Burguillos et al. 2011), CD23(Hunot et al. 1999) or CD163(Pey et al. 2014) is 
also increased. Interestingly, microglial cells in PD brain express C1q(Depboylu et al. 2011), 
which is implicated in the clearance of apoptotic cells through phagocytosis. Additionally, 
increased levels of glucocorticoid receptors(Ros-Bernal et al. 2011), a regulator of 
inflammation, nitric oxide synthase(Hunot et al. 1996) (NOS) and inducible NOS(Knott et al. 
2000) (iNOS), expression of which is increased during inflammatory events, as well as 
lipocortin-1(Knott et al. 2000), an anti-inflammatory molecule, were detected in microglial 
cells in PD brain.  
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In contrast to microglial cells, the activated status of astrocytes is more controversial in brains 
of PD patients, since some studies detect astrogliosis through increased expression of 
GFAP(Mythri et al. 2011; Lastres-Becker et al. 2012) or ICAM-1(Miklossy et al. 2006) while 
others did not(Mirza et al. 1999; Tong et al. 2015). However, whether astrogliosis is triggered 
or not, inflammatory events seemed to affect astrocytes since increased levels of 
myeloperoxidase(Choi et al. 2005a), a key oxidant-producing enzyme during inflammation, 
milk fat globule-EGF factor 8 (Kinugawa et al. 2013) (MFGE8), a factor involved in 
phagocytic recognition, as well as heme oxygenase-1(Schipper et al. 2009) (HO-1), an 
antioxidant enzyme involved in the regulation of the inflammatory process, were reported 
specifically in astrocytes in the parkinsonian brain. Importantly, infiltration of peripheral 
immune cells could also participates in the neuroinflammatory response in PD since LFA-1-
positive leukocytes(Miklossy et al. 2006), CD8-positive and CD4-positive T cells(Brochard et 
al. 2009) were found in the SN of PD patients. 
Inflammatory response can be harmful for the neuronal cells because of the release of pro-
inflammatory agents. In the parkinsonian brain, higher levels of cytokines like interleukin (IL) 
1β(Mogi et al. 1994a; Hunot et al. 1999) (IL-1β), IL-2(Mogi et al. 1996b), IL-6(Mogi et al. 
1994a), tumor necrosis factor α(Mogi et al. 1994b; Hunot et al. 1999) (TNFα), S100B(Sathe 
et al. 2012), interferon ɣ(Mogi et al. 2007; Hunot et al. 1999) and its receptor(Hashioka et al. 
2009), as well as chemokine (C-X-C motif) ligand 12 (CXCL12) and its receptor C-X-C 
chemokine receptor type 4(Shimoji et al. 2009) (CXCR4) were detected. Finally, at the 
neuronal level, inflammation appears ongoing since dopaminergic neurons of the SN express 
higher levels of cyclooxygenase-2(Teismann et al. 2003), the rate-limiting enzyme in 
prostaglandin E2 synthesis. Moreover, the nuclear fraction of NF-κB, a transcription factor 
activated during inflammatory response, is increased in the same neuronal population(Soós et 
al. 2004). 
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Mitochondrial abnormalities and oxidative stress 
Mitochondrial abnormalities and energy deficits 
Mitochondria play a prominent role in energy metabolism and many lines of evidence suggest 
mitochondrial dysfunctions and energy deficits in PD (Table 5). The first studies on 
mitochondrial dysfunction in PD documented deficiency of mitochondrial Complex I in the 
PD SN(Schapira et al. 1989; Schapira et al. 1990). Subsequent analyses have confirmed the 
important role of Complex I in PD(Morais et al. 2014). Other studies observed deregulated 
expression of several mitochondrial proteins in PD brain e.g. the molecular chaperones 
prohibitin(Ferrer et al. 2007), the outer mitochondrial membrane VDAC1(Chu et al. 2014), 
the mitochondrial import machinery translocase of outer membrane 40 TOM40(Bender et al. 
2013), the serine protease HtrA2(Plun-Favreau et al. 2007), or hemoglobins α and β(Ferrer et 
al. 2011; Shephard et al. 2014). The PD associated protein parkin and PINK1 would also play 
a key role in mitochondrial dynamics (for review see (Pickrell and Youle 2015)). In this 
respect, AF6, a key regulator of PINK1/parkin-mediated autophagy, is less expressed in the 
SN of PD patients. Glucose metabolism is dysregulated in PD, particularly with the increased 
levels of pentose phosphate pathway enzymes glucose-6-phosphate dehydrogenase (G6PD) 
and 6-phosphogluconate dehydrogenase (6PGD) leading to elevated production of NADPH, a 
sign of oxidative stress(Dunn et al. 2014).  
Finally, total and mitochondrial oxygen uptake(Navarro et al. 2009) is reduced. This is 
consistent with the evidences for impaired oxidative phosphorylation in PD brain 
samples(Keeney et al. 2006; Parker et al. 2008; Hattori et al. 1993; Navarro et al. 2009; 
Schapira et al. 1990; Schapira et al. 1989). Three reasons are evoked to explain this 
observation: complex I expression seemed to be reduced(Moisoi et al. 2009; Keeney et al. 
2006), particularly the NADH dehydrogenase 6 subunit(She et al. 2011) (ND6); catalytic 
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subunits of complex I were found to contain oxidized proteins(Keeney et al. 2006); 
mitochondrial DNA may develop some mutations in PD (including the mitochondrial 
polymerase gamma gene(Orsucci et al. 2011)), which could explain defects in mitochondrial 
respiration(Sanders et al. 2014; Bender et al. 2006; Lin et al. 2013). ATP synthase levels have 
been reported to be reduced in the SN of PD patients(Ferrer et al. 2007). As a consequence of 
the deficit of mitochondrial electron transport chain, high-energy phosphates such as ATP and 
phosphocreatine as final acceptors of energy from mitochondrial oxidative phosphorylation 
are reduced. In contrast, low-energy metabolites such as ADP and inorganic phosphate were 
within normal ranges(Hattingen et al. 2009). Since complex I is considered as one of the main 
source of reactive oxygen species in the cell, its abnormal function could lead to increased 
oxidative stress. This could explain the observed increase in the oxidative damage of 
mitochondrial proteins(Navarro et al. 2009).  
 
Oxidative stress 
A large number of studies indicate that oxidative stress is considered as a major contributing 
factor in the pathogenesis of PD (Table 5). The levels of total oxidized proteins(Alam et al. 
1997; Choi et al. 2005b; Yoritaka et al. 1996; Mythri et al. 2011) are highly increased in 
several brain areas, either through carbonylation or nitrosylation, and more particularly 
mitochondrial proteins(Shimura-Miura et al. 1999; Navarro et al. 2009). Moreover, oxidative 
stress sensor of nucleolar integrity is disrupted in dopaminergic neurons of the SN(Rieker et 
al. 2011), while Nrf2 (nuclear factor erythroid 2-related factor 2), which is translocated into 
the nucleus in response to oxidative stress, shows increased nuclear and reduced cytoplasmic 
levels(Ramsey et al. 2007). Antioxidant proteins levels and activities are particularly 
deregulated: biliverdin reductase(Reynolds et al. 2008), superoxide dismutase 
(SOD)(Radunović et al. 1997; Marttila et al. 1988; Choi et al. 2005b; Ferrer et al. 2007; 
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Navarro et al. 2009), sestrin-2(Zhou et al. 2013), selenoprotein P(Bellinger et al. 2012), 
osteopontin(Maetzler et al. 2007), NAD(P)H quinone oxidoreductase(van Muiswinkel et al. 
2004), MTH1(Nakabeppu et al. 2007), MUTYH(Arai et al. 2006; Shimura-Miura et al. 1999) 
(mutY Homolog), nitrosylated peroxiredoxin-2(Fang et al. 2007), levels and/or activities are 
increased, while catalase and peroxidase activity(Ambani et al. 1975) are decreased. This 
decrease in peroxidase activity can be controlled through phosphorylation. Interestingly, 
phosphorylated peroxyredoxin-2 and 3 levels are increased in the PD brain(Qu et al. 2007; 
Angeles et al. 2011).  
The glutathione system, which is responsible for the detoxification of reactive oxygen and 
nitrogen species, appeared to be deregulated in PD patients. While oxidized glutathione levels 
are normal, reduced glutathione levels are severely decreased in the SN of PD patients(Sian et 
al. 1994; Pearce et al. 1997; Riederer et al. 1989). Moreover, several enzymes of the 
glutathione system including ɣ-glutamyltranspeptidase(Mythri et al. 2011; Sian et al. 1994), 
glutathione peroxidase(Power et al. 2002; Mythri et al. 2011), glutathione-S-
transferase(Reynolds et al. 2008) levels and/or activities are altered in the PD brain.  
One consequence of oxidative stress in PD is DNA damage. Indeed, in PD patients, DNA is 
severely oxidized(Du et al. 2009), and mitochondrial and nuclear DNA presented a higher 
number of mutations(Zhang et al. 2002; Ozawa et al. 1997; Lin et al. 2013; Sanders et al. 
2014; Bender et al. 2006) than control brains. In response to DNA damage, defense 
mechanisms against oxidative damage to nucleic acids involving MTH1(Shimura-Miura et al. 
1999), MUTYH(Arai et al. 2006) and OGG1 (8-oxoguanine DNA-glycosylase 1) (Fukae et 
al. 2005) as well as DNA repair proteins such as poly(ADP-ribose) polymerase(Soós et al. 
2004) (PARP), TNF Receptor Associated Protein(Vilotti et al. 2012) (TRAPP), DNA 
polymerase δ(Camins et al. 2010) and ataxia telangiectasia muted(Camins et al. 2010) (ATM) 
are activated in PD brain. 
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Abnormal protein removal and degradation 
The ubiquitin-proteasome system (UPS) and autophagy-lysosome pathway (ALP) are the two 
most important cellular mechanisms that repair or remove abnormal proteins(Korolchuk et al. 
2010). Since PD is characterized by the presence of misfolded and aggregated proteins that 
forms Lewy bodies, alterations in abnormal protein removal could be implicated in its 
pathogenesis through impairment of either UPS, ALP, or both mechanisms (Table 6).  
 
Ubiquitin-proteasome system (UPS) 
The UPS is the principal mechanism for protein catabolism in the mammalian cytosol and 
nucleus. Degradation of a protein via the UPS involves two steps: the conjugation, which 
consists in the covalent attachment of ubiquitin molecules to the substrate protein, and the 
subsequent degradation of the tagged protein by the proteasome(Korolchuk et al. 2010). 
Several lines of evidence obtained from the postmortem study of PD brains suggest that the 
UPS is dysregulated in this pathology (Table 6). First, total ubiquinated protein level is 
dramatically increased in the striatum of PD patients(Lonskaya et al. 2013). This could be the 
result of defective expression of several ubiquitin ligase or deubiquitinase. In line with this 
hypothesis, SKP1A(Mandel et al. 2007) (S-phase kinase-associated protein 1A), 
NEDD4(Tofaris et al. 2011) (neural precursor cell expressed, developmentally down-
regulated 4), USP9X(Rott et al. 2011) (ubiquitin specific peptidase 9, X-linked) and 
TRIM9(Tanji et al. 2010) (tripartite motif containing 9) have been shown to be deregulated in 
the SN of parkinsonian brains. Also, parkin, a protein encoded by a gene that when mutate, is 
associated with familial PD, possesses ubiquitin ligase activities(Seirafi et al. 2015). 
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The increase in total ubiquinated protein level could also be explained by proteasomal 
dysfunctions. Indeed, the activity of the 26S proteasome is decreased in several structures of 
the parkinsonian brain(Wills et al. 2010). The 20S proteasome, which correspond to the 
catalytic core of the protein complex, is also underexpressed(McNaught and Jenner 2001; Chu 
et al. 2009; Wills et al. 2010), explaining its weaker chymotriptic, tryptic and postacidic 
activities(McNaught et al. 2003; McNaught and Jenner 2001) in the SN of PD brains. More 
precisely, the α-subunit of 20S proteasome is underexpressed in this structure(McNaught et 
al. 2003), a result confirmed by Bukhatwa et al.(Bukhatwa et al. 2010) who reported that α4 
and α6 subunit levels were specifically decreased in dopaminergic neurons of the SN. This 
decrease in α subunits of the 20S appears to be restricted to the SN since α6 subunit levels are 
increased in the striatum(Nakamura et al. 2006). Likewise, the regulatory core of the 
proteasome called 19S (or PA700) has also been reported to be underexpressed in the SN but 
overexpressed in the Str(McNaught et al. 2003). PA28 (also known as 11S), an alternate 
regulator that can replace 19S proteasome, did not seem to be involved in the 
pathology(McNaught et al. 2003). 
 
Lysosome, macroautophagy and chaperone-mediated autophagy (CMA) 
Autophagy is a cellular process by which cytoplasmic materials are delivered to and degraded 
in the lysosome to maintain cellular homeostasis. Depending on the mode of cargo delivery to 
the lysosome, autophagy can be subdivided into three subtypes: macroautophagy, 
microautophagy, and chaperone-mediated autophagy (CMA)(Wu et al. 2014). While 
microautophagy had not been assessed in parkinsonian brains, evidence suggests that 
macroautophagy, CMA and lysosomal degradation are deregulated in PD patients (Table 6).  
Macroautophagy, which is the most universal form of autophagy, is characterized by the 
formation of autophagosomes that are capable of disposing of protein aggregates and 
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damaged organelles(Korolchuk et al. 2010). Macroautophagy appears to be implicated in PD 
pathogenesis since several key proteins driving this cellular process are deregulated. Beclin-1, 
which is responsible for the formation and the maturation of autophagosomes, is increased in 
the SN of PD patients(Rohn and Catlin 2011; Miki et al. 2015), as well as LC3II(Dehay et al. 
2010), an autophagosome marker. However, no difference was observed between control and 
PD levels of unc-51 like autophagy activating kinase 1 (ULK1), ULK2 or 
phosphatidylinositol 3-kinase VPS34(Miki et al. 2015). In contrast to autophagy, CMA is a 
process by which selected cytosolic proteins are directly targeted to the lysosome for 
degradation (for more details see (Kaushik and Cuervo 2012)). Impairment of CMA function 
is implicated in PD pathogenesis since heat shock cognate 70(Alvarez-Erviti et al. 2010; 
Mandel et al. 2009) (HSC70), a protein responsible for the translocation of targeted substrate 
into the lysosome, as well as its lysosomal surface receptor lysosomal-associated membrane 
protein 2(Murphy et al. 2014; Alvarez-Erviti et al. 2010) (LAMP2) are less expressed in 
several structures of PD brain. This deficit in CMA in PD brain could explain why levels of 
MEF2D (myocyte enhancer factor 2D), a transcription factor degraded through CMA, are 
increased in the striatum of PD patients(She et al. 2011).  
At the lysosomal level, Anglade and coworkers(Anglade et al. 1997) observed that the 
number of autophagic vacuoles is drastically decreased in the dopaminergic neurons of PD 
SN. At the molecular level, lysosomal markers like the structural protein Lysosome 
Associated Membrane Protein 1(Chu et al. 2009; Dehay et al. 2010) (LAMP1), the lysosomal 
P-type ATPase ATP13A2(Dehay et al. 2012), glucocerebrosidase(Gegg et al. 2012; Murphy 
et al. 2014) and its interacting partner lysosomal integral membrane protein type-2(Rothaug et 
al. 2014) (LIMP-2) as well as Heat Shock Protein 73(Chu et al. 2009) (HSP73), all were 
decreased in the SN of PD patients. Moreover, several enzymes that participate in the 
degradation of proteins (Cathepsins A(Murphy et al. 2014), B(Mantle et al. 1995), D(Murphy 
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et al. 2014; Chu et al. 2009; Mantle et al. 1995), H(Mantle et al. 1995), L(Mantle et al. 1995), 
and dipeptidyl aminopeptidase(Mantle et al. 1996)) had abnormal levels or activities. 
Interestingly, the expression of two transcription factors crucially involved in the ALP, 
namely transcription factor EB(Decressac et al. 2013) (TFEB) and LMX1B(Laguna et al. 
2015) (LIM homeobox transcription factor 1 beta), were found to be reduced in the 
dopaminergic neurons of the SN of PD patients.  
 
Apoptosis and transduction pathways 
Several lines of evidence suggest that neurons degenerate mostly through an apoptotic 
pathway in PD. The SN of PD patients contains hallmarks of apoptosis, such as nuclear 
condensation, chromatin fragmentation(Tompkins et al. 1997) or TUNEL (terminal 
deoxynucleotidyl transferase dUTP nick end labeling) positive cells(Mochizuki et al. 1996). 
At the molecular level, two different routes can trigger caspase-mediated apoptotic processes: 
the intrinsic and the extrinsic apoptotic pathway (Table 7). Since the intrinsic apoptosis 
pathway is activated following intracellular events such as ER stress or cell cycle re-entry, we 
will first review these topics. 
 
ER stress 
ER is recognized as the site of synthesis and folding of proteins. Abnormalities in ER 
functions lead to the accumulation and aggregation of unfolded proteins. To avoid this protein 
accumulation, transmembrane receptors located in the ER detect the onset of ER stress and 
activate the unfolded protein response (UPR). If UPR fails in reinstating normal ER function, 
apoptotic cell death ensues (for review see (Szegezdi et al. 2006)). Few studies have focused 
on ER stress and UPR markers in PD brains (Table 7). Hoozemans et al. showed that an 
increased number of dopaminergic neurons of the SN express the UPR activation markers 
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phosphorylated pancreatic ER kinase (PERK) and phosphorylated eukaryotic initiation factor 
2α (eIF2α)(Hoozemans et al. 2007), as well as phosphorylated inositol-requiring enzyme 1 
(IRE1α)(Hoozemans et al. 2012). In another study, increased nuclear levels of activated, 
phosphorylated double-strand RNA dependent protein kinase (PKR), a kinase which activates 
eIF2α, were also reported(Bando et al. 2005). Finally, homocysteine-induced endoplasmic 
reticulum protein (HERP), a stress-response protein localized in the ER membrane, is also 
overexpressed in the SN of PD patients(Slodzinski et al. 2009). 
 
Cell cycle re-entry 
Recent results indicate that re-entry into the cell cycle may constitute a common pathway 
involved during neurodegeneration(Folch et al. 2012). Consistent with this hypothesis (Table 
7), neurons with extra copies of chromosomes 18 and X(Höglinger et al. 2004) as well as 
increased levels of normal and phosphorylated retinoblastoma protein (pRb), a molecular 
trigger of cell-cycle progression, were observed in dopaminergic neurons in the postmortem 
SN of PD patients(Jordan-Sciutto et al. 2003). Moreover, p25/Cdk5 (cyclin-dependent kinase 
5), which phosphorylates pRb(Hamdane et al. 2005), is overexpressed in PD(Alvira et al. 
2008; Rubio de la Torre et al. 2009), as well as the Cdk5 activator p35(Rubio de la Torre et 
al. 2009). In line with this view, SN dopaminergic neurons of PD patients has been shown to 
be immunoreactive for proliferating cell nuclear antigen(Höglinger et al. 2004) (PCNA), a 
subunit of DNA polymerase, E2F-1, a mitosis-linked transcription factor(Höglinger et al. 
2004; Alvira et al. 2008), and cyclin D1(Camins et al. 2010).  
 
Intrinsic apoptotic pathway 
Cellular stress such as ER stress or DNA damage activates B cell lymphoma 2 (BCL-2) 
homology 3 (BH3)-only proteins leading to BCL-2-associated X protein (Bax) activation. 
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Interestingly, Bax levels were shown to be increased specifically in dopaminergic 
neurons(Tatton 2000), and in Lewy body containing neurons(Hartmann et al. 2001a). The 
anti-apoptotic Bcl-2, which binds activated Bax, was shown to be overexpressed in several 
structures of PD brains(Letters et al. 1996; Marshall et al. 1997). Once activated, Bax triggers 
mitochondrial outer membrane permeabilisation. As a consequence, cytochrome c is released 
into the cytosol. In PD SN and LC, neurons exhibit a higher level of cytochrome c(Kawamoto 
et al. 2014). Moreover, total cytochrome c content is increased in PD temporal cortex while 
mitochondrial content is decreased(Jiang et al. 2012). Consistent with a permeabilisation of 
the mitochondrial membrane, endonuclease G, a mitochondrial pro-apoptotic nuclease, is also 
found in the nucleus of PD dopaminergic neurons(Büttner et al. 2013). Once released in the 
cytosol, cytochrome c binds apoptotic protease-activating factor 1 (APAF1), inducing its 
oligomerization and thereby forming a structure termed the apoptosome that recruits and 
activates an initiator caspase, caspase 9. In TH neurons of PD SN, increased levels of both 
APAF1(Kawamoto et al. 2014) and activated caspase-9(Viswanath et al. 2001; Kawamoto et 
al. 2014) have been reported. When activated, caspase-9 cleaves and recruits executioner 
caspase-3, leading to apoptosis. In PD brain, caspase-3 activity(Mogi et al. 2000) and 
levels(Tatton 2000; Jiang et al. 2012) are increased in the SN and temporal cortex. In contrast 
to these observations, Hartmann et al.(Hartmann et al. 2000) observed a significant decrease 
of caspase-3-positive pigmented neurons in the SNpc of PD patients compared to controls, 
interpreted as an increased sensitivity to the pathological process of caspase-3 containing 
neurons. Finally, p53 and its active, phosphorylated form (pp53), a transcription factor that 
controls the expression and the activation of several proteins implicated in the apoptotic 
process (including Bax and Apaf1), is overexpressed in several brain areas of PD 
patients(Mogi et al. 2007; Sunico et al. 2013; Camins et al. 2010).  
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Extrinsic pathway 
The activation of the extrinsic apoptotic pathway depends on external factors(Elmore 2007) 
that as previously mentioned, could be involved in PD pathogenesis, such as neurotrophic 
factor deprivation or inflammation. During inflammatory episodes, cytokines and pro-
inflammatory agents like TNF-α or FasL are released by glial cells. These pro-inflammatory 
agents can trigger the extrinsic apoptotic pathway by interacting with TNF receptor (TNFR) 
family. Interestingly, in PD postmortem brains, TNF receptor I (TNFRI, also known as p55) 
and its effector protein TNFR1-associating protein with a death domain (TRADD) levels have 
both been shown to be increased in the SN(Mogi et al. 2000) and the temporal cortex(Jiang et 
al. 2012). Reduced expression of Fas, another receptor potentially responsible for the 
activation of the extrinsic apoptotic pathway, and its ligand FasL have been observed in 
neurons of the SN of PD patients, while their levels were increased in reactive astrocytes of 
the same structure(Ferrer et al. 2000). Mogi(Mogi et al. 1996a) et al., showed that soluble Fas 
expression was increased in the caudate nucleus and putamen of parkinsonian brains. 
Moreover, levels of Fas-associated factor-1, which can serve as an enhancer of apoptosis 
initiated through Fas, was overexpressed(Betarbet et al. 2008).  
Activation of TNFRI or Fas by pro-inflammatory agents converges with the activation by 
cleavage of caspase-8. Increased levels of activated caspase-8 have been observed in 
dopaminergic neurons of the SN in PD patients(Viswanath et al. 2001), and an increased 
number of TH neurons of the same structure expressing activated caspase-8 was also 
reported(Hartmann et al. 2001b). Of interest, the number of TH neurons expressing Fas-
associating protein with a death domain (FADD), which participates in the auto-proteolytic 
cleavage of caspase-8, is reduced in the SN of PD patients, suggesting that these neurons are 
more prone to degeneration(Hartmann et al. 2002). Once activated, caspase-8 may in turn 
cleave effector caspases such as caspase-3 or caspase-1, whose activities are increased in the 
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SN of PD patients(Mogi et al. 2000). Moreover, Bid and its post-translationally activated, 
truncated form tBid through caspase-8-mediated cleavage, are also increased in the cytoplasm 
and mitochondria of PD brains(Jiang et al. 2012). 
 
Other form of cell death 
Lee and coworkers(Lee et al. 2013) demonstrated that parthanatos, a form of cell death 
induced by excessive poly-ADP-ribose polymers, could be implicated in PD since the level of 
these polymers is strongly increased as well as AIMP2, which is thought to mediate 
parthanatos-induced cell death.  
 
Transduction pathways and transcription factors 
Several changes in the activation of transcription factors and transduction pathways occur in 
PD brain (Table 7). Since cellular stress might be of great importance in PD pathogenesis, 
many studies focused on nuclear factor-kappa B (NF-κB), a transcription factors involved in 
cellular responses to inflammation and oxidative stress(Morgan and Liu 2011). Many lines of 
evidence suggest that NF-κB is activated in PD. First, negative regulator of NF-κB activation 
like RING finger protein 11 (RNF11) has reduced expression in PD(Pranski et al. 2013). 
Total NF-κB levels were found elevated in the SN of PD patients(Mogi et al. 2007), as well 
as its constituting subunit p50(Reynolds et al. 2008) and p65(Ghosh et al. 2009; Reynolds et 
al. 2008). These increased levels were found in the cytosol as well as in the nucleus(Reynolds 
et al. 2008). Interestingly, increased nuclear levels are reported in the dopaminergic neurons 
of the SN of PD patients(Hunot et al. 1997; Soós et al. 2004). Moreover, levels of normal and 
phosphorylated p53 protein, known to be involved in apoptosis, are increased in PD 
brains(Mogi et al. 2007; Folch et al. 2012; Sunico et al. 2013). 
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Akt, a prosurvival factor(Zhang et al. 2011), appears to be involved in the pathogenesis of PD 
since its midbrain levels are significantly reduced(Timmons et al. 2009). This was also 
observed in TH neurons of the SN(Malagelada et al. 2008), and phosphorylated levels of 
GSK-3β (Glycogen synthase kinase-3β), which is negatively regulated by Akt, are increased 
in PD striatum(Wills et al. 2010). Importantly, levels of S473-phosphorylated (activated) Akt 
were reduced in this neuronal population(Malagelada et al. 2008) in TH neurons. To explain 
this observation, Malagelada et al. suggested the involvement of Redd1, an endogenous 
inhibitor of Akt expression and activation, which levels are increased in the parkinsonian 
SN(Malagelada et al. 2008). 
The microtubule-associated protein kinase (MAPK) pathway is important for cell 
survival(Cargnello and Roux 2011). One of its members, ERK1/2 (Extracellular signal-
regulated kinase 1/2), and its downstream target CREB (cAMP response element-binding) 
were reported as less phosphorylated in PD striatum(Kurup et al. 2015). Contrasting results 
were observed in the frontal cortex of PD patients(Price et al. 2010). Two other members of 
the MAPK family, the prodeath c-Jun N-terminal kinase (JNK) and p38, displayed increased 
levels in the SN of PD patients(Hu et al. 2011). Accordingly, Hunot et al. reported increased 
activated JNK downstream target c-jun in PD dopaminergic neurons(Hunot et al. 2004). Of 
interest, apoptosis signal-regulating kinase 1 (ASK1), which regulated the activation of both 
JNK and p38, was also found to be more activated(Hu et al. 2011). Moreover, membrane 
levels of 14-3-3ζ phosphorylated at S58, which causes release of the pro-apoptotic protein 
ASK1 and cell death in response to oxidative stress(Zhou et al. 2009), are decreased in PD 
patients(Slone et al. 2015). Finally, a number of other transcription factors crucially involved 
in cell survival following cellular stress such as PGC1α(Eschbach et al. 2015; Shin et al. 
2011) (peroxisome proliferator-activated receptor gamma, coactivator 1 alpha), MEF2D(Gao 
et al. 2014; Chu et al. 2011; She et al. 2011) or Nurr1(Chu et al. 2006) (Nuclear receptor 
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related 1) are underexpressed in PD brain, while Nfatc4 (Nuclear Factor Of Activated T-Cells, 
Cytoplasmic, Calcineurin-Dependent 4) nuclear localization is increased(Caraveo et al. 2014).  
 
Other proteins 
Expression of several other proteins have also been shown to be altered in PD and in 
particular structural and cytoskeleton proteins. Connexin-36(Schwab et al. 2014) and α-
tubulin(Reynolds et al. 2008) levels are increased, while actin(Reynolds et al. 2008) and L-
plastin(Reynolds et al. 2008) are reduced. Abnormal microtubule-associated protein 2 (MAP-
2) nuclear labelling has been reported(D’Andrea et al. 2001). Of interest, tau phosphorylation 
status is, as in Alzheimer’s disease, highly modified(Duka et al. 2013; Wills et al. 2010). 
Levels of synaptic proteins like the SNARE assembly complex(Sharma et al. 2012), SNAP-
25 or syntaxin-1(Garcia-Reitböck et al. 2010)are all modified as well as extracellular matrix 
components MMP-2 (matrix metalloprotease 2) and TIMP-1(Lorenzl et al. 2002) (TIMP 
Metallopeptidase Inhibitor 1), lipid transporters apolipoprotein (apo) D(Ordoñez et al. 2006) 
(ApoD), E(Wilhelmus et al. 2011a) (ApoE) and ApoE receptor LRP1(Wilhelmus et al. 
2011a). Finally, the expression of several phospholipid biosynthetic enzymes as calcium-
stimulated phospholipase A2, phosphatidylserine synthase, 
phosphocholinecytidylyltransferase and phosphoethanolaminecytidylyltransferase are also 
increased(Ross et al. 2001). 
 
Incidental Lewy body disease 
Incidental Lewy body disease (ILBD) is usually considered as a prodromal state of PD 
characterised by the absence of motor symptoms but the presence of a variety of non-motor 
abnormalities. At the cellular level, ILBD is characterised by a moderate nigral neuronal 
loss(Dijkstra et al. 2014) and Lewy pathology(Iacono et al. 2015), decreased striatal 
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dopaminergic immunoreactivity(DelleDonne et al. 2008; Dickson et al. 2008; Beach et al. 
2008), olfactory bulb abnormalities(Driver-Dunckley et al. 2014), and microglial 
activation(Doorn et al. 2014). However, few studies have focused on the molecular changes. 
L-ferritin and copper levels are decreased(Davies et al. 2014),(Koziorowski et al. 2007), while 
mitochondrial DNA mutations(Lin et al. 2012) and Bcl-2(Marshall et al. 1997) levels are 
increased. Several evidences suggest that oxidative stress and mitochondrial function are also 
altered in ILBD(Dexter et al. 1994; Dalfó et al. 2005). 
 
Conclusions 
There are comprehensive data derived from postmortem PD brains that have demonstrated 
that multiple pathways and cellular functions are modified at the molecular level in late-stage 
pathology. During our review of the literature, we observed that postmortem studies were 
mainly restricted to the nigrostriatal pathway, while cerebral structures that are affected before 
this pathway during the course of the disease (i.e. olfactory bulb and medulla 
oblongata(Goedert et al. 2014)) or where cell loss is also important in the disease (such as 
locus coeruleus(Zarow et al. 2015) and pedunculopontine nucleus(Hirsch et al. 1987)) are 
poorly studied at the molecular level. This is a disadvantage in our efforts to understand the 
effects of pathogenesis on non-dopaminergic systems and in particular the biochemical 
changes that underlie non-motor features in PD. In addition, there is an opportunity by this 
means to investigate areas ‘ahead of the pathology’ i.e. those regions that might be affected by 
early molecular derangements, but not neurodegeneration. This would provide insight into the 
evolving nature of the molecular pathogenesis of PD, and represent the same principle as 
addressed in those studies on Incidental Lewy Body disease (see above) but in pathologically 
proven PD brain. Animal studies in PD field focus exclusively on nigrostriatal cell 
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degeneration and death, which could somehow explain the high rate failure of drugs that were 
tested successfully in animal models but failed clinically in PD patients. 
 
On the other hand, while postmortem brain studies represent an efficient way to improve our 
understanding of the pathology, it also presents some limitations. The sample size is often 
limited because it is still difficult to obtain brain tissue, and postmortem delay will affect the 
quality of tissues, and thus the preservation of proteins especially when some are more 
vulnerable than others(Ferrer et al. 2008). Braak stage of collected postmortem brains is also 
usually highly heterogeneous, challenging further comparisons. These factors, together with 
heterogeneity of PD could render the interpretation of postmortem studies very difficult, even 
sometimes uncertain if sampling is not rigorously performed.  
 
Acknowledgements 
The authors would like to thank Ilya Chumakov for his critical review of the manuscript. 
 
Conflicts of interest 
The authors declare no conflicts of interest. 
  
29 
 
References 
Ahlskog J. E., Richelson E., Nelson A., Kelly P. J., Okazaki H., Tyce G. M., Heerden J. a van, 
Stoddard S. L., Carmichael S. W. (1991) Reduced D2 dopamine and muscarinic cholinergic 
receptor densities in caudate specimens from fluctuating parkinsonian patients. Ann. Neurol. 30, 
185–191. 
Aksenova M. V., Aksenov M. Y., Payne R. M., Trojanowski J. Q., Schmidt M. L., Carney J. M., 
Butterfield D. A., Markesbery W. R. (1999) Oxidation of cytosolic proteins and expression of 
creatine kinase BB in frontal lobe in different neurodegenerative disorders. Dement. Geriatr. 
Cogn. Disord. 10, 158–165. 
Alam Z. I., Daniel S. E., Lees A. J., Marsden D. C., Jenner P., Halliwell B. (1997) A generalised 
increase in protein carbonyls in the brain in Parkinson’s but not incidental Lewy body disease. J. 
Neurochem. 69, 1326–9. 
Allen A. M., MacGregor D. P., Chai S. Y., Donnan G. A., Kaczmarczyk S., Richardson K., Kalnins 
R., Ireton J., Mendelsohn F. A. (1992) Angiotensin II receptor binding associated with 
nigrostriatal dopaminergic neurons in human basal ganglia. Ann. Neurol. 32, 339–344. 
Alvarez-Erviti L., Rodriguez-Oroz M. C., Cooper J. M., Caballero C., Ferrer I., Obeso J. A., Schapira 
A. H. V. (2010) Chaperone-Mediated Autophagy Markers in Parkinson Disease Brains. Arch. 
Neurol. 67, 1464–1472. 
Alvira D., Ferrer I., Gutierrez-Cuesta J., Garcia-Castro B., Pallàs M., Camins A. (2008) Activation of 
the calpain/cdk5/p25 pathway in the girus cinguli in Parkinson’s disease. Parkinsonism Relat. 
Disord. 14, 309–13. 
Ambani L. M., Woert M. H. Van, Murphy S. (1975) Brain peroxidase and catalase in Parkinson 
disease. Arch. Neurol. 32, 114–8. 
Andringa G., Lam K. Y., Chegary M., Wang X., Chase T. N., Bennett M. C., Branch E. T., 
Neurosciences B. R. (2004) Tissue transglutaminase catalyzes the formation of alpha-synuclein 
crosslinks in Parkinson’s disease. FASEB J. 18, 932–934. 
Angeles D. C., Gan B.-H., Onstead L., Zhao Y., Lim K.-L., Dachsel J., Melrose H., et al. (2011) 
Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-
induced neuronal death. Hum. Mutat. 32, 1390–7. 
Anglade P., Vyas S., Javoy-Agid F., Herrero M. T., Michel P. P., Marquez J., Mouatt-Prigent A., 
Ruberg M., Hirsch E. C., Agid Y. (1997) Apoptosis and autophagy in nigral neurons of patients 
with Parkinson’s disease. Histol. Histopathol. 12, 25–31. 
Arai T., Fukae J., Hatano T., Kubo S., Ohtsubo T., Nakabeppu Y., Mori H., Mizuno Y., Hattori N. 
(2006) Up-regulation of hMUTYH, a DNA repair enzyme, in the mitochondria of substantia 
nigra in Parkinson’s disease. Acta Neuropathol. 112, 139–145. 
Arawaka S., Wada M., Goto S., Karube H., Sakamoto M., Ren C.-H., Koyama S., et al. (2006) The 
role of G-protein-coupled receptor kinase 5 in pathogenesis of sporadic Parkinson’s disease. J. 
Neurosci. 26, 9227–38. 
Ayton S., Lei P., Duce J. a., Wong B. X. W., Sedjahtera A., Adlard P. a., Bush A. I., Finkelstein D. I. 
(2013) Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. Ann. Neurol. 
73, 554–559. 
Bando Y., Onuki R., Katayama T., Manabe T., Kudo T., Taira K., Tohyama M. (2005) Double-strand 
RNA dependent protein kinase (PKR) is involved in the extrastriatal degeneration in Parkinson’s 
disease and Huntington's disease. Neurochem. Int. 46, 11–8. 
30 
 
Bandopadhyay R., Kingsbury A. E., Cookson M. R., Reid A. R., Evans I. M., Hope A. D., Pittman A. 
M., et al. (2004) The expression of DJ-1 (PARK7) in normal human CNS and idiopathic 
Parkinson’s disease. Brain 127, 420–30. 
Banerjee C., Nyengaard J. R., Wevers A., Vos R. a de, Jansen Steur E. N., Lindstrom J., Pilz K., 
Nowacki S., Bloch W., Schröder H. (2000) Cellular expression of alpha7 nicotinic acetylcholine 
receptor protein in the temporal cortex in Alzheimer’s and Parkinson's disease-a stereological 
approach. Neurobiol. Dis. 7, 666–72. 
Barrachina M., Castaño E., Dalfó E., Maes T., Buesa C., Ferrer I. (2006) Reduced ubiquitin C-
terminal hydrolase-1 expression levels in dementia with Lewy bodies. Neurobiol. Dis. 22, 265–
73. 
Beach T. G., Adler C. H., Sue L. I., Peirce J. B., Bachalakuri J., Dalsing-Hernandez J. E., Lue L. F., et 
al. (2008) Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta 
Neuropathol. 115, 445–51. 
Bellinger F. P., Raman A. V, Rueli R. H., Bellinger M. T., Dewing A. S., Seale L. A., Andres M. A., 
et al. (2012) Changes in selenoprotein P in substantia nigra and putamen in Parkinson’s disease. 
J. Parkinsons. Dis. 2, 115–26. 
Bender A., Desplats P., Spencer B., Rockenstein E., Adame A., Elstner M., Laub C., et al. (2013) 
TOM40 mediates mitochondrial dysfunction induced by α-synuclein accumulation in 
Parkinson’s disease. PLoS One 8, e62277. 
Bender A., Krishnan K. J., Morris C. M., Taylor G. a, Reeve A. K., Perry R. H., Jaros E., et al. (2006) 
High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson 
disease. Nat. Genet. 38, 515–7. 
Betarbet R., Anderson L. R., Gearing M., Hodges T. R., Fritz J. J., Lah J. J., Levey A. I. (2008) Fas-
associated factor 1 and Parkinson’s disease. Neurobiol. Dis. 31, 309–15. 
Braak H., Braak E. (2000) Pathoanatomy of Parkinson’s disease. J. Neurol. 247, II3–I10. 
Braak H., Rüb U., Gai W. P., Tredici K. Del (2003) Idiopathic Parkinson’s disease: Possible routes by 
which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. 
Neural Transm. 110, 517–536. 
Brochard V., Combadière B., Prigent A., Laouar Y., Perrin A., Beray-Berthat V., Bonduelle O., et al. 
(2009) Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a 
mouse model of Parkinson disease. J. Clin. Invest. 119, 182–92. 
Bukhatwa S., Zeng B.-Y., Rose S., Jenner P. (2010) A comparison of changes in proteasomal subunit 
expression in the substantia nigra in Parkinson’s disease, multiple system atrophy and 
progressive supranuclear palsy. Brain Res. 1326, 174–83. 
Burghaus L., Schütz U., Krempel U., Lindstrom J., Schröder H. (2003) Loss of nicotinic acetylcholine 
receptor subunits α4 and α7 in the cerebral cortex of Parkinson patients. Parkinsonism Relat. 
Disord. 9, 243–246. 
Burguillos M. a, Deierborg T., Kavanagh E., Persson A., Hajji N., Garcia-Quintanilla A., Cano J., et 
al. (2011) Caspase signalling controls microglia activation and neurotoxicity. Nature 472, 319–
24. 
Büttner S., Habernig L., Broeskamp F., Ruli D., Vögtle F. N., Vlachos M., Macchi F., et al. (2013) 
Endonuclease G mediates α-synuclein cytotoxicity during Parkinson’s disease. EMBO J. 32, 
3041–3054. 
Camins A., Pizarro J. G., Alvira D., Gutierrez-Cuesta J., la Torre A. V. de, Folch J., Sureda F. X., et 
al. (2010) Activation of ataxia telangiectasia muted under experimental models and human 
31 
 
Parkinson’s disease. Cell. Mol. Life Sci. 67, 3865–82. 
Caraveo G., Auluck P. K., Whitesell L., Chung C. Y., Baru V., Mosharov E. V, Yan X., et al. (2014) 
Calcineurin determines toxic versus beneficial responses to α-synuclein. Proc. Natl. Acad. Sci. 
U. S. A. 111, E3544–52. 
Cargnello M., Roux P. P. (2011) Activation and function of the MAPKs and their substrates, the 
MAPK-activated protein kinases. Microbiol. Mol. Biol. Rev. 75, 50–83. 
Chaudhuri K. R., Healy D. G., Schapira A. H. V (2006) Non-motor symptoms of Parkinson’s disease: 
diagnosis and management. Lancet. Neurol. 5, 235–45. 
Chauhan A., Jeans A. F. (2015) Is Parkinson’s disease truly a prion-like disorder? An appraisal of 
current evidence. Neurol. Res. Int. 2015, 345285. 
Chauhan N. B., Siegel G. J., Lee J. M. (2001) Depletion of glial cell line-derived neurotrophic factor 
in substantia nigra neurons of Parkinson’s disease brain. J. Chem. Neuroanat. 21, 277–288. 
Cho H. J., Liu G., Jin S. M., Parisiadou L., Xie C., Yu J., Sun L., et al. (2013) MicroRNA-205 
regulates the expression of Parkinson’s disease-related leucine-rich repeat kinase 2 protein. Hum. 
Mol. Genet. 22, 608–20. 
Choi D.-H., Cristóvão A. C., Guhathakurta S., Lee J., Joh T. H., Beal M. F., Kim Y.-S. (2012) 
NADPH Oxidase 1-Mediated Oxidative Stress Leads to Dopamine Neuron Death in Parkinson’s 
Disease. Antioxid. Redox Signal. 16, 1033–1045. 
Choi D.-H., Kim Y.-J., Kim Y.-G., Joh T. H., Beal M. F., Kim Y.-S. (2011) Role of matrix 
metalloproteinase 3-mediated alpha-synuclein cleavage in dopaminergic cell death. J. Biol. 
Chem. 286, 14168–77. 
Choi D.-K., Pennathur S., Perier C., Tieu K., Teismann P., Wu D.-C., Jackson-Lewis V., et al. (2005a) 
Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson’s disease 
in mice. J. Neurosci. 25, 6594–600. 
Choi J., Rees H. D., Weintraub S. T., Levey A. I., Chin L.-S., Li L. (2005b) Oxidative modifications 
and aggregation of Cu,Zn-superoxide dismutase associated with Alzheimer and Parkinson 
diseases. J. Biol. Chem. 280, 11648–55. 
Choi M. S., Nakamura T., Cho S.-J., Han X., Holland E. a, Qu J., Petsko G. a, Yates J. R., Liddington 
R. C., Lipton S. a (2014) Transnitrosylation from DJ-1 to PTEN attenuates neuronal cell death in 
parkinson’s disease models. J. Neurosci. 34, 15123–31. 
Chu Y., Dodiya H., Aebischer P., Olanow C. W., Kordower J. H. (2009) Alterations in lysosomal and 
proteasomal markers in Parkinson’s disease: relationship to alpha-synuclein inclusions. 
Neurobiol. Dis. 35, 385–98. 
Chu Y., Goldman J. G., Kelly L., He Y., Waliczek T., Kordower J. H. (2014) Abnormal alpha-
synuclein reduces nigral voltage-dependent anion channel 1 in sporadic and experimental 
Parkinson’s disease. Neurobiol. Dis. 69, 1–14. 
Chu Y., Le W., Kompoliti K., Jankovic J., Mufson E. J., Kordower J. H. (2006) Nurr1 in Parkinson’s 
disease and related disorders. J. Comp. Neurol. 494, 495–514. 
Chu Y., Mickiewicz A. L., Kordower J. H. (2011) α-synuclein aggregation reduces nigral myocyte 
enhancer factor-2D in idiopathic and experimental Parkinson’s disease. Neurobiol. Dis. 41, 71–
82. 
Chung K. K. K., Thomas B., Li X., Pletnikova O., Troncoso J. C., Marsh L., Dawson V. L., Dawson 
T. M. (2004) S-nitrosylation of parkin regulates ubiquitination and compromises parkin’s 
protective function. Science 304, 1328–1331. 
32 
 
Citron B. A., Suo Z., SantaCruz K., Davies P. J. A., Qin F., Festoff B. W. (2002) Protein crosslinking, 
tissue transglutaminase, alternative splicing and neurodegeneration, in Neurochem. Int., Vol. 40, 
pp. 69–78. 
Cooper-Knock J., Kirby J., Ferraiuolo L., Heath P. R., Rattray M., Shaw P. J. (2012) Gene expression 
profiling in human neurodegenerative disease. Nat. Rev. Neurol. 8, 518–530. 
Court J. A., Piggott M. A., Lloyd S., Cookson N., Ballard C. G., McKeith I. G., Perry R. H., Perry E. 
K. (2000) Nicotine binding in human striatum: Elevation in schizophrenia and reductions in 
dementia with Lewy bodies, Parkinson’s disease and Alzheimer's disease and in relation to 
neuroleptic medication. Neuroscience 98, 79–87. 
D’Andrea M. R., Ilyin S., Plata-Salaman C. R. (2001) Abnormal patterns of microtubule-associated 
protein-2 (MAP-2) immunolabeling in neuronal nuclei and Lewy bodies in Parkinson’s disease 
substantia nigra brain tissues. Neurosci. Lett. 306, 137–140. 
Dalfó E., Portero-Otín M., Ayala V., Martínez A., Pamplona R., Ferrer I. (2005) Evidence of oxidative 
stress in the neocortex in incidental Lewy body disease. J. Neuropathol. Exp. Neurol. 64, 816–
30. 
Davies K. M., Bohic S., Carmona A., Ortega R., Cottam V., Hare D. J., Finberg J. P. M. M., et al. 
(2014) Copper pathology in vulnerable brain regions in Parkinson’s disease. Neurobiol. Aging 
35, 858–866. 
Dawson T. M., Dawson V. L. (2010) The role of parkin in familial and sporadic Parkinson’s disease. 
Mov. Disord. 25, 32–39. 
Decressac M., Kadkhodaei B., Mattsson B., Laguna A., Perlmann T., Björklund A. (2012) α-
Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine 
neurons. Sci. Transl. Med. 4, 156–63. 
Decressac M., Mattsson B., Weikop P., Lundblad M., Jakobsson J., Björklund A. (2013) TFEB-
mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity. Proc. Natl. 
Acad. Sci. U. S. A. 110, E1817–26. 
Dehay B., Bové J., Rodríguez-Muela N., Perier C., Recasens A., Boya P., Vila M. (2010) Pathogenic 
lysosomal depletion in Parkinson’s disease. J. Neurosci. 30, 12535–44. 
Dehay B., Ramirez A., Martinez-Vicente M., Perier C., Canron M.-H. M.-H., Doudnikoff E., Vital A., 
Vila M., Klein C., Bezard E. (2012) Loss of P-type ATPase ATP13A2/PARK9 function induces 
general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc. Natl. 
Acad. Sci. 109, 9611–9616. 
DelleDonne A., Klos K. J., Fujishiro H., Ahmed Z., Parisi J. E., Josephs K. A., Frigerio R., et al. 
(2008) Incidental Lewy body disease and preclinical Parkinson disease. Arch. Neurol. 65, 1074–
80. 
Depboylu C., Höllerhage M., Schnurrbusch S., Brundin P., Oertel W. H., Schrattenholz A., Höglinger 
G. U. (2012) Neuregulin-1 receptor tyrosine kinase ErbB4 is upregulated in midbrain 
dopaminergic neurons in Parkinson disease. Neurosci. Lett. 531, 209–14. 
Depboylu C., Schäfer M. K.-H., Arias-Carrión O., Oertel W. H., Weihe E., Höglinger G. U. (2011) 
Possible involvement of complement factor C1q in the clearance of extracellular neuromelanin 
from the substantia nigra in Parkinson disease. J. Neuropathol. Exp. Neurol. 70, 125–132. 
Desplats P., Spencer B., Coffee E., Patel P., Michael S., Patrick C., Adame A., Rockenstein E., 
Masliah E. (2011) Alpha-synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for 
epigenetic alterations in Lewy body diseases. J. Biol. Chem. 286, 9031–7. 
Devi L., Raghavendran V., Prabhu B. M., Avadhani N. G., Anandatheerthavarada H. K. (2008) 
33 
 
Mitochondrial import and accumulation of alpha-synuclein impair complex I in human 
dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 283, 9089–9100. 
Dexter D. T., Sian J., Rose S., Hindmarsh J. G., Mann V. M., Cooper J. M., Wells F. R., Daniel S. E., 
Lees A. J., Schapira A. H. (1994) Indices of oxidative stress and mitochondrial function in 
individuals with incidental Lewy body disease. Ann. Neurol. 35, 38–44. 
Dexter D. T., Wells F. R., Lees A. J., Agid F., Agid Y., Jenner P., Marsden C. D. (1989) Increased 
nigral iron content and alterations in other metal ions occurring in brain in Parkinson’s disease. J. 
Neurochem. 52, 1830–1836. 
Dickson D. W., Fujishiro H., DelleDonne A., Menke J., Ahmed Z., Klos K. J., Josephs K. A., et al. 
(2008) Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease. Acta 
Neuropathol. 115, 437–44. 
Dijkstra A. A., Voorn P., Berendse H. W., Groenewegen H. J., Rozemuller A. J. M., Berg W. D. J. van 
de (2014) Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson’s disease. 
Mov. Disord. 29, 1244–51. 
Doorn K. J., Moors T., Drukarch B., Berg W. D. van de, Lucassen P. J., Dam A.-M. van (2014) 
Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of 
incidental Lewy body disease cases and Parkinson’s disease patients. Acta Neuropathol. 
Commun. 2, 90. 
Driver-Dunckley E., Adler C. H., Hentz J. G., Dugger B. N., Shill H. A., Caviness J. N., Sabbagh M. 
N., Beach T. G. (2014) Olfactory dysfunction in incidental Lewy body disease and Parkinson’s 
disease. Parkinsonism Relat. Disord. 20, 1260–2. 
Du Y., Wooten M. C., Wooten M. W. (2009) Oxidative damage to the promoter region of 
SQSTM1/p62 is common to neurodegenerative disease. Neurobiol. Dis. 35, 302–10. 
Duerson K., Woltjer R. L., Mookherjee P., Leverenz J. B., Montine T. J., Bird T. D., Pow D. V., 
Rauen T., Cook D. G. (2009) Detergent-insoluble EAAC1/EAAT3 aberrantly accumulates in 
hippocampal neurons of Alzheimer’s disease patients. Brain Pathol. 19, 267–278. 
Dufty B. M., Warner L. R., Hou S. T., Jiang S. X., Gomez-Isla T., Leenhouts K. M., Oxford J. T., 
Feany M. B., Masliah E., Rohn T. T. (2007) Calpain-cleavage of alpha-synuclein: connecting 
proteolytic processing to disease-linked aggregation. Am. J. Pathol. 170, 1725–38. 
Duka V., Lee J.-H., Credle J., Wills J., Oaks A., Smolinsky C., Shah K., Mash D. C., Masliah E., 
Sidhu A. (2013) Identification of the sites of tau hyperphosphorylation and activation of tau 
kinases in synucleinopathies and Alzheimer’s diseases. PLoS One 8, e75025. 
Dunn L., Allen G. F. G., Mamais A., Ling H., Li A., Duberley K. E., Hargreaves I. P., et al. (2014) 
Dysregulation of glucose metabolism is an early event in sporadic Parkinson’s disease. 
Neurobiol. Aging 35, 1111–1115. 
Duty S., Jenner P. (2011) Animal models of Parkinson’s disease: a source of novel treatments and 
clues to the cause of the disease. Br. J. Pharmacol. 164, 1357–91. 
Elmore S. (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35, 495–516. 
Eschbach J., Einem B. von, Müller K., Bayer H., Scheffold A., Morrison B. E., Rudolph K. L., et al. 
(2015) Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α 
deregulation and α-synuclein oligomerization. Ann. Neurol. 77, 15–32. 
Fang J., Nakamura T., Cho D., Gu Z., Lipton S. A. (2007) S-nitrosylation of peroxiredoxin 2 promotes 
oxidative stress-induced neuronal cell death in Parkinson’s disease. Proc. Natl. Acad. Sci. U. S. 
A. 104, 18742–18747. 
34 
 
Faucheux B. A., Hauw J.-J., Agid Y., Hirsch E. C. (1997) The density of 125-transferrin binding sites 
on perikarya of melanized neurons of the subtantia nigra is decreased in Parkinson’s disease. 
Brain Res 749, 170–174. 
Faucheux B. A., Nillesse N., Damier P., Spik G., Mouatt-Prigent A., Pierce A., Leveugle B., Kubis N., 
Hauw J. J., Agid Y. (1995) Expression of lactoferrin receptors is increased in the mesencephalon 
of patients with Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 92, 9603–9607. 
Ferrer I., Blanco R. (2000) N-myc and c-myc expression in Alzheimer disease, Huntington disease and 
Parkinson disease. Mol. Brain Res. 77, 270–276. 
Ferrer I., Blanco R., Cutillas B., Ambrosio S. (2000) Fas and Fas-L expression in Huntington’s disease 
and Parkinson's disease. Neuropathol. Appl. Neurobiol. 26, 424–433. 
Ferrer I., Gómez A., Carmona M., Huesa G., Porta S., Riera-Codina M., Biagioli M., Gustincich S., 
Aso E. (2011) Neuronal hemoglobin is reduced in Alzheimer’s disease, argyrophilic grain 
disease, Parkinson's disease, and Dementia with Lewy bodies. J. Alzheimer’s Dis. 23, 537–550. 
Ferrer I., Martinez A., Boluda S., Parchi P., Barrachina M. (2008) Brain banks: Benefits, limitations 
and cautions concerning the use of post-mortem brain tissue for molecular studies. Cell Tissue 
Bank. 9, 181–194. 
Ferrer I., Perez E., Dalfó E., Barrachina M. (2007) Abnormal levels of prohibitin and ATP synthase in 
the substantia nigra and frontal cortex in Parkinson’s disease. Neurosci. Lett. 415, 205–9. 
Folch J., Junyent F., Verdaguer E., Auladell C., Pizarro J. G., Beas-Zarate C., Pallàs M., Camins A. 
(2012) Role of cell cycle re-entry in neurons: A common apoptotic mechanism of neuronal cell 
death. Neurotox. Res. 22, 195–207. 
Fukae J., Sato S., Shiba K., Sato K., Mori H., Sharp P. a, Mizuno Y., Hattori N. (2009) Programmed 
cell death-2 isoform1 is ubiquitinated by parkin and increased in the substantia nigra of patients 
with autosomal recessive Parkinson’s disease. FEBS Lett. 583, 521–5. 
Fukae J., Takanashi M., Kubo S., Nishioka K., Nakabeppu Y., Mori H., Mizuno Y., Hattori N. (2005) 
Expression of 8-oxoguanine DNA glycosylase (OGG1) in Parkinson’s disease and related 
neurodegenerative disorders. Acta Neuropathol. 109, 256–62. 
Galazka-Friedman J., Bauminger E. R., Koziorowski D., Friedman A. (2004) Mössbauer spectroscopy 
and ELISA studies reveal differences between Parkinson’s disease and control substantia nigra. 
Biochim. Biophys. Acta - Mol. Basis Dis. 1688, 130–136. 
Gao L., She H., Li W., Zeng J., Zhu J., Jones D. P., Mao Z., Gao G., Yang Q. (2014) Oxidation of 
Survival Factor MEF2D in Neuronal Death and Parkinson’s Disease. Antioxid. Redox Signal. 20, 
2936–2949. 
Garcia-Reitböck P., Anichtchik O., Bellucci A., Iovino M., Ballini C., Fineberg E., Ghetti B., et al. 
(2010) SNARE protein redistribution and synaptic failure in a transgenic mouse model of 
Parkinson’s disease. Brain 133, 2032–44. 
Gargalidis-Moudanos C., Pizzinat N., Javoy-Agid F., Remaury A., Parini A. (1997) I2-imidazoline 
binding sites and monoamine oxidase activity in human postmortem brain from patients with 
Parkinson’s disease. Neurochem. Int. 
Gegg M. E., Burke D., Heales S. J. R., Cooper J. M., Hardy J., Wood N. W., Schapira A. H. V (2012) 
Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann. Neurol. 72, 
455–63. 
Gerlach M., Gsell W., Kornhuber J., Jellinger K., Krieger V., Pantucek F., Vock R., Riederer P. 
(1996) A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and 
glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome. Brain 
35 
 
Res 741, 142–152. 
Ghosh A., Roy A., Matras J., Brahmachari S., Gendelman H. E., Pahan K. (2009) Simvastatin inhibits 
the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of 
Parkinson’s disease. J. Neurosci. 29, 13543–56. 
Giasson B. I., Duda J. E., Murray I. V, Chen Q., Souza J. M., Hurtig H. I., Ischiropoulos H., 
Trojanowski J. Q., Lee V. M. (2000) Oxidative damage linked to neurodegeneration by selective 
alpha-synuclein nitration in synucleinopathy lesions. Science 290, 985–989. 
Goedert M., Falcon B., Clavaguera F., Tolnay M. (2014) Prion-like mechanisms in the pathogenesis of 
tauopathies and synucleinopathies. Curr. Neurol. Neurosci. Rep. 14, 495. 
Good P. F., Olanow C. W., Perl D. P. (1992) Neuromelanin-containing neurons of the substantia nigra 
accumulate iron and aluminum in Parkinson’s disease: a LAMMA study. Brain Res. 593, 343–6. 
Goodchild R. E., Court J. A., Hobson I., Piggott M. A., Perry R. H., Ince P., Jaros E., Perry E. K. 
(1999) Distribution of histamine H3-receptor binding in the normal human basal ganglia: 
comparison with Huntington’s and Parkinson's disease cases. Eur. J. Neurosci. 11, 449–56. 
Gotti C., Moretti M., Bohr I., Ziabreva I., Vailati S., Longhi R., Riganti L., et al. (2006) Selective 
nicotinic acetylcholine receptor subunit deficits identified in Alzheimer’s disease, Parkinson's 
disease and dementia with Lewy bodies by immunoprecipitation. Neurobiol. Dis. 23, 481–9. 
Griffiths P. D., Perry R. H., Crossman A. R. (1994) A detailed anatomical analysis of neurotransmitter 
receptors in the putamen and caudate in Parkinson’s disease and Alzheimer's disease. Neurosci. 
Lett. 169, 68–72. 
Griffiths P. D., Sambrook M. A., Perry R., Crossman A. R. (1990) Changes in benzodiazepine and 
acetylcholine receptors in the globus pallidus in Parkinson’s disease. J. Neurol. Sci. 100, 131–
136. 
Guerreiro P. S., Huang Y., Gysbers A., Cheng D., Gai W. P., Outeiro T. F., Halliday G. M. (2013) 
LRRK2 interactions with α-synuclein in Parkinson’s disease brains and in cell models. J. Mol. 
Med. 91, 513–22. 
Güzey C., Allard P., Brännström T., Spigset O. (2012) Radioligand binding to brain dopamine and 
serotonin receptors and transporters in Parkinson’s disease: relation to gene polymorphisms. Int. 
J. Neurosci. 122, 124–32. 
Halliday G. M., Ophof A., Broe M., Jensen P. H., Kettle E., Fedorow H., Cartwright M. I., Griffiths F. 
M., Shepherd C. E., Double K. L. (2005) Alpha-synuclein redistributes to neuromelanin lipid in 
the substantia nigra early in Parkinson’s disease. Brain 128, 2654–64. 
Halliday G. M., Stevens C. H. (2011) Glia: initiators and progressors of pathology in Parkinson’s 
disease. Mov. Disord. 26, 6–17. 
Halliday G. M., Tredici K. Del, Braak H. (2006) Critical appraisal of brain pathology staging related 
to presymptomatic and symptomatic cases of sporadic Parkinson’s disease. J. Neural Transm. 
Suppl. 70, 99–103. 
Hamdane M., Bretteville A., Sambo A.-V., Schindowski K., Bégard S., Delacourte A., Bertrand P., 
Buée L. (2005) p25/Cdk5-mediated retinoblastoma phosphorylation is an early event in neuronal 
cell death. J. Cell Sci. 118, 1291–8. 
Hartmann A., Hunot S., Michel P. P., Muriel M. P., Vyas S., Faucheux B. A., Mouatt-Prigent A., et al. 
(2000) Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic 
neurons in Parkinson’s disease. Proc. Natl. Acad. Sci. U. S. A. 97, 2875–80. 
Hartmann A., Michel P. P., Troadec J. D., Mouatt-Prigent A., Faucheux B. A., Ruberg M., Agid Y., 
36 
 
Hirsch E. C. (2001a) Is bax a mitochondrial mediator in apoptotic death of dopaminergic neurons 
in Parkinson’s disease? J. Neurochem. 76, 1785–1793. 
Hartmann A., Mouatt-Prigent A., Faucheux B. A., Agid Y., Hirsch E. C. (2002) FADD: A link 
between TNF family receptors and caspases in Parkinson’s disease. Neurology 58, 308–10. 
Hartmann A., Troadec J. D., Hunot S., Kikly K., Faucheux B. A., Mouatt-Prigent A., Ruberg M., Agid 
Y., Hirsch E. C. (2001b) Caspase-8 is an effector in apoptotic death of dopaminergic neurons in 
Parkinson’s disease, but pathway inhibition results in neuronal necrosis. J. Neurosci. 21, 2247–
2255. 
Hashioka S., Klegeris A., Schwab C., McGeer P. L. (2009) Interferon-gamma-dependent cytotoxic 
activation of human astrocytes and astrocytoma cells. Neurobiol. Aging 30, 1924–35. 
Haskin J., Szargel R., Shani V., Mekies L. N., Rott R., Lim G. G. Y., Lim K.-L., Bandopadhyay R., 
Wolosker H., Engelender S. (2013) AF-6 is a positive modulator of the PINK1/parkin pathway 
and is deficient in Parkinson’s disease. Hum. Mol. Genet. 22, 2083–96. 
Hattingen E., Magerkurth J., Pilatus U., Mozer A., Seifried C., Steinmetz H., Zanella F., Hilker R. 
(2009) Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial 
dysfunction in early and advanced Parkinson’s disease. Brain 132, 3285–97. 
Hattori N., Ikebe S., Tanaka M., Ozawa T., Mizuno Y. (1993) Immunohistochemical studies on 
complexes I, II, III, and IV of mitochondria in Parkinson’s disease. Adv. Neurol. 
Henderson-Smith A., Chow D., Meechoovet B., Aziz M., Jacobson S. a, Shill H. a, Sabbagh M. N., et 
al. (2013) SMG1 identified as a regulator of Parkinson’s disease-associated alpha-synuclein 
through siRNA screening. PLoS One 8, e77711. 
Hirsch E. C., Brandel J.-P. P., Galle P., Javoy-Agid F., Agid Y. (1991) Iron and aluminum increase in 
the substantia nigra of patients with Parkinson’s disease: an X-ray microanalysis. J. Neurochem. 
56, 446–51. 
Hirsch E. C., Graybiel A. M., Duyckaerts C., Javoy-Agid F. (1987) Neuronal loss in the 
pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. 
Proc. Natl. Acad. Sci. U. S. A. 84, 5976–80. 
Höglinger G. U., Rizk P., Muriel M. P., Duyckaerts C., Oertel W. H., Caille I., Hirsch E. C. (2004) 
Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat. Neurosci. 7, 
726–35. 
Hoogendijk W. J. G., Purba J. S., Hofman M. A., Vos R. A. I. De, Jansen E. N. H., Swaab D. F. 
(1998) Depression in Parkinson’s disease is not accompanied by more corticotropin-releasing 
hormone expressing neurons in the hypothalamic paraventricular nucleus. Biol. Psychiatry 43, 
913–917. 
Hoozemans J. J. M., Haastert E. S. van, Eikelenboom P., Vos R. a I. de, Rozemuller J. M., Scheper W. 
(2007) Activation of the unfolded protein response in Parkinson’s disease. Biochem. Biophys. 
Res. Commun. 354, 707–11. 
Hoozemans J. J. M., Haastert E. S. van, Nijholt D. a T., Rozemuller A. J. M., Scheper W. (2012) 
Activation of the unfolded protein response is an early event in Alzheimer’s and Parkinson's 
disease. Neurodegener. Dis. 10, 212–5. 
Howitt J., Gysbers A. M., Ayton S., Carew-Jones F., Putz U., Finkelstein D. I., Halliday G. M., Tan 
S.-S. (2014) Increased Ndfip1 in the substantia nigra of Parkinsonian brains is associated with 
elevated iron levels. PLoS One 9, e87119. 
Hu X., Weng Z., Chu C. T., Zhang L., Cao G., Gao Y., Signore A., et al. (2011) Peroxiredoxin-2 
protects against 6-hydroxydopamine-induced dopaminergic neurodegeneration via attenuation of 
37 
 
the apoptosis signal-regulating kinase (ASK1) signaling cascade. J. Neurosci. 31, 247–61. 
Hunot S., Boissière F., Faucheux B., Brugg B., Mouatt-Prigent A., Agid Y., Hirsch E. C. C. (1996) 
Nitric oxide synthase and neuronal vulnerability in Parkinson’s disease. Neuroscience 72, 355–
363. 
Hunot S., Brugg B., Ricard D., Michel P. P., Muriel M. P., Ruberg M., Faucheux B. A., Agid Y., 
Hirsch E. C. (1997) Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of 
patients with Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 94, 7531–7536. 
Hunot S., Dugas N., Faucheux B., Hartmann A., Tardieu M., Debré P., Agid Y., Dugas B., Hirsch E. 
C. (1999) FcepsilonRII/CD23 is expressed in Parkinson’s disease and induces, in vitro, 
production of nitric oxide and tumor necrosis factor-alpha in glial cells. J. Neurosci. 19, 3440–7. 
Hunot S., Vila M., Teismann P., Davis R. J., Hirsch E. C., Przedborski S., Rakic P., Flavell R. A. 
(2004) JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a 
mouse model of Parkinson’s disease. Proc. Natl. Acad. Sci. U. S. A. 101, 665–670. 
Hurley M. J., Brandon B., Gentleman S. M., Dexter D. T. (2013) Parkinson’s disease is associated 
with altered expression of CaV1 channels and calcium-binding proteins. Brain 136, 2077–97. 
Iacono D., Geraci-Erck M., Rabin M. L., Adler C. H., Serrano G., Beach T. G., Kurlan R. (2015) 
Parkinson disease and incidental Lewy body disease: Just a question of time? Neurology 85, 
1670–9. 
Iczkiewicz J., Jackson M. J., Smith L. a, Rose S., Jenner P. (2006) Osteopontin expression in 
substantia nigra in MPTP-treated primates and in Parkinson’s disease. Brain Res. 1118, 239–50. 
Imam S. Z., Zhou Q., Yamamoto A., Valente A. J., Ali S. F., Bains M., Roberts J. L., Kahle P. J., 
Clark R. a, Li S. (2011) Novel regulation of parkin function through c-Abl-mediated tyrosine 
phosphorylation: implications for Parkinson’s disease. J. Neurosci. 31, 157–63. 
Imamura K., Hishikawa N., Ono K., Suzuki H., Sawada M., Nagatsu T., Yoshida M., Hashizume Y. 
(2005) Cytokine production of activated microglia and decrease in neurotrophic factors of 
neurons in the hippocampus of Lewy body disease brains. Acta Neuropathol. 109, 141–50. 
Imamura K., Hishikawa N., Sawada M., Nagatsu T., Yoshida M., Hashizume Y. (2003) Distribution 
of major histocompatibility complex class II-positive microglia and cytokine profile of 
Parkinson’s disease brains. Acta Neuropathol. 106, 518–26. 
Itoh K., Weis S., Mehraein P., Müller-Höcker J. (1997) Defects of cytochrome c oxidase in the 
substantia nigra of Parkinson’s disease: An immunohistochemical and morphometric study. Mov. 
Disord. 12, 9–16. 
Iwakura Y., Piao Y.-S., Mizuno M., Takei N., Kakita A., Takahashi H., Nawa H. (2005) Influences of 
dopaminergic lesion on epidermal growth factor-ErbB signals in Parkinson’s disease and its 
model: neurotrophic implication in nigrostriatal neurons. J. Neurochem. 93, 974–83. 
Jellinger K., Kienzl E., Rumpelmair G., Riederer P., Stachelberger H., Ben-Shachar D., Youdim M. B. 
(1992) Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. 
J. Neurochem. 59, 1168–1171. 
Jiang H., He P., Adler C. H., Shill H., Beach T. G., Li R., Shen Y. (2012) Bid signal pathway 
components are identified in the temporal cortex with Parkinson disease. Neurology 79, 1767–
73. 
Jordan-Sciutto K. L., Dorsey R., Chalovich E. M., Hammond R. R., Achim C. L. (2003) Expression 
patterns of retinoblastoma protein in Parkinson disease. J. Neuropathol. Exp. Neurol. 62, 68–74. 
Kastner A., Hirsch E. C., Agid Y., Javoy-Agid F. (1993) Tyrosine hydroxylase protein and messenger 
38 
 
RNA in the dopaminergic nigral neurons of patients with Parkinson’s disease. Brain Res. 606, 
341–345. 
Kaushik S., Cuervo A. M. (2012) Chaperone-mediated autophagy: a unique way to enter the lysosome 
world. Trends Cell Biol. 22, 407–17. 
Kawamoto Y., Ito H., Ayaki T., Takahashi R. (2014) Immunohistochemical localization of 
apoptosome-related proteins in Lewy bodies in Parkinson’s disease and dementia with Lewy 
bodies. Brain Res. 1571, 39–48. 
Keeney P. M., Xie J., Capaldi R. a, Bennett J. P. (2006) Parkinson’s disease brain mitochondrial 
complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J. 
Neurosci. 26, 5256–64. 
Kinugawa K., Monnet Y., Lu L., Bekaert A. J., Théry C., Mallat Z., Hirsch E. C., Hunot S. (2013) 
MFGE8 does not orchestrate clearance of apoptotic neurons in a mouse model of Parkinson’s 
disease. Neurobiol. Dis. 51, 192–201. 
Knott C., Stern G., Kingsbury A., Welcher A. A., Wilkin G. P. (2002) Elevated glial brain-derived 
neurotrophic factor in Parkinson’s diseased nigra. Park. Relat. Disord. 8, 329–341. 
Knott C., Stern G., Wilkin G. P. (2000) Inflammatory regulators in Parkinson’s disease: iNOS, 
lipocortin-1, and cyclooxygenases-1 and -2. Mol. Cell. Neurosci. 16, 724–39. 
Ko H. S., Kim S. W., Sriram S. R., Dawson V. L., Dawson T. M. (2006) Identification of far upstream 
element-binding protein-1 as an authentic Parkin substrate. J. Biol. Chem. 281, 16193–6. 
Ko H. S., Lee Y., Shin J.-H., Karuppagounder S. S., Gadad B. S., Koleske A. J., Pletnikova O., 
Troncoso J. C., Dawson V. L., Dawson T. M. (2010) Phosphorylation by the c-Abl protein 
tyrosine kinase inhibits parkin’s ubiquitination and protective function. Proc. Natl. Acad. Sci. U. 
S. A. 107, 16691–16696. 
Korolchuk V. I., Menzies F. M., Rubinsztein D. C. (2010) Mechanisms of cross-talk between the 
ubiquitin-proteasome and autophagy-lysosome systems. FEBS Lett. 584, 1393–1398. 
Korutla L., Furlong H., Mackler S. (2014) NAC1, A POZ/BTB protein interacts with Parkin and may 
contribute to Parkinson’s disease. Neuroscience 257, 86–95. 
Koziorowski D., Friedman A., Arosio P., Santambrogio P., Dziewulska D. (2007) ELISA reveals a 
difference in the structure of substantia nigra ferritin in Parkinson’s disease and incidental Lewy 
body compared to control. Parkinsonism Relat. Disord. 13, 214–8. 
Kurup P. K., Xu J., Videira R. A., Ononenyi C., Baltazar G., Lombroso P. J., Nairn A. C. (2015) 
STEP61 is a substrate of the E3 ligase parkin and is upregulated in Parkinson’s disease. Proc. 
Natl. Acad. Sci. U. S. A. 112, 1202–7. 
Laguna A., Schintu N., Nobre A., Alvarsson A., Volakakis N., Jacobsen J. K., Gómez-Galán M., et al. 
(2015) Dopaminergic control of autophagic-lysosomal function implicates Lmx1b in Parkinson’s 
disease. Nat. Neurosci. 18. 
Lastres-Becker I., Ulusoy A., Innamorato N. G., Sahin G., Rábano A., Kirik D., Cuadrado A. (2012) 
α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal 
death and inflammation in early-stage Parkinson’s disease. Hum. Mol. Genet. 21, 3173–92. 
LaVoie M. J., Ostaszewski B. L., Weihofen A., Schlossmacher M. G., Selkoe D. J. (2005) Dopamine 
covalently modifies and functionally inactivates parkin. Nat. Med. 11, 1214–21. 
Leake A., Perry E. K., Perry R. H., Jabeen S., Fairbairn A. F., McKeith I. G., Ferrier I. N. (1991) 
Neocortical concentrations of neuropeptides in senile dementia of the Alzheimer and Lewy body 
type: Comparison with Parkinson’s disease and severity correlations. Biol. Psychiatry 29, 357–
39 
 
364. 
Lee Y. Y.-I., Karuppagounder S. S., Shin J.-H., Lee Y. Y.-I., Ko H. S., Swing D., Jiang H., et al. 
(2013) Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. Nat. 
Neurosci. 16, 1392–400. 
Letters E. N., Mogi M., Harada M., Kondo T., Mizuno Y., Narabayashi H., Riederer P., Nagatsu T. 
(1996) bcl-2 protein is increased in the brain from parkinsonian patients. Neurosci. Lett. 215, 
137–139. 
Leveugle B., Faucheux B. A., Bouras C., Nillesse N., Spik G., Hirsch E. C., Agid Y., Hof P. R. (1996) 
Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of 
Parkinson’s disease cases. Acta Neuropathol. 91, 566–72. 
Li J.-Y., Englund E., Holton J. L., Soulet D., Hagell P., Lees A. J., Lashley T., et al. (2008) Lewy 
bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease 
propagation. Nat. Med. 14, 501–503. 
Lin M. T., Cantuti-castelvetri I., Ph D., Zheng K., Katie E., Tan Y. B., Arzberger T., et al. (2013) 
Somatic mitochondrial DNA mutations in early Parkinson’s and incidental Lewy body disease. 
Ann. Neurol. 71, 850–854. 
Lin M. T., Cantuti-Castelvetri I., Zheng K., Jackson K. E., Tan Y. B., Arzberger T., Lees A. J., 
Betensky R. A., Beal M. F., Simon D. K. (2012) Somatic mitochondrial DNA mutations in early 
Parkinson and incidental Lewy body disease. Ann. Neurol. 71, 850–4. 
Lloyd K. G., Shemen L., Hornykiewicz O. (1977) Distribution of high affinity sodium-independent 
[3H]gamma-aminobutyric acid binding in the human brain: alterations in Parkinson’s disease. 
Brain Res. 127, 269–278. 
Loeffler D. a, Camp D. M., Conant S. B. (2006) Complement activation in the Parkinson’s disease 
substantia nigra: an immunocytochemical study. J. Neuroinflammation 3, 29. 
Lonskaya I., Hebron M. L., Algarzae N. K., Desforges N., Moussa C. E.-H. (2013) Decreased parkin 
solubility is associated with impairment of autophagy in the nigrostriatum of sporadic 
Parkinson’s disease. Neuroscience 232, 90–105. 
Lorenzl S., Albers D. S., Narr S., Chirichigno J., Beal M. F. (2002) Expression of MMP-2, MMP-9, 
and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain 
tissue of Parkinson’s disease. Exp. Neurol. 178, 13–20. 
Maetzler W., Berg D., Schalamberidze N., Melms A., Schott K., Mueller J. C., Liaw L., Gasser T., 
Nitsch C. (2007) Osteopontin is elevated in Parkinson’s disease and its absence leads to reduced 
neurodegeneration in the MPTP model. Neurobiol. Dis. 25, 473–82. 
Mahul-Mellier  a.-L., Fauvet B., Gysbers A., Dikiy I., Oueslati A., Georgeon S., Lamontanara  a. J., et 
al. (2014) c-Abl phosphorylates alpha-synuclein and regulates its degradation: implication for 
alpha-synuclein clearance and contribution to the pathogenesis of Parkinson’s disease. Hum. 
Mol. Genet. 23, 2858–2879. 
Malagelada C., Jin Z. H., Greene L. (2008) RTP801 is induced in Parkinson’s disease and mediates 
neuron death by inhibiting Akt phosphorylation/activation. J. Neurosci. 28, 14363–71. 
Malagelada C., Ryu E. J., Biswas S. C., Jackson-Lewis V., Greene L. a (2006) RTP801 is elevated in 
Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson’s 
disease by a mechanism involving mammalian target of rapamycin inactivation. J. Neurosci. 26, 
9996–10005. 
Mandel S. A., Fishman T., Youdim M. B. H. (2007) Gene and protein signatures in sporadic 
Parkinson’s disease and a novel genetic model of PD. Parkinsonism Relat. Disord. 13, S242–
40 
 
S247. 
Mandel S. a., Fishman-Jacob T., Youdim M. B. H. (2009) Modeling sporadic Parkinson’s disease by 
silencing the ubiquitin E3 ligase component, SKP1A. Park. Relat. Disord. 15, S148–S151. 
Mann V. M., Cooper J. M., Daniel S. E., Srai K., Jenner P., Marsden C. D., Schapira A. H. (1994) 
Complex I, iron, and ferritin in Parkinson’s disease substantia nigra. Ann. Neurol. 36, 876–81. 
Mantle D., Falkous G., Ishiura S., Blanchard P. J., Perry E. K. (1996) Comparison of proline 
endopeptidase activity in brain tissue from normal cases and cases with Alzheimer’s disease, 
Lewy body dementia, Parkinson's disease and Huntington's disease. Clin. Chim. Acta 249, 129–
139. 
Mantle D., Falkous G., Ishiura S., Perry R. H., Perry E. K. (1995) Comparison of cathepsin protease 
activities in brain tissue from normal cases and cases with Alzheimer’s disease, Lewy body 
dementia, Parkinson's disease and Huntington's disease. J. Neurol. Sci. 131, 65–70. 
Marshall K. A., Daniel S. E., Cairns N., Jenner P., Halliwell B. (1997) Upregulation of the anti-
apoptotic protein Bcl-2 may be an early event in neurodegeneration: studies on Parkinson’s and 
incidental Lewy body disease. Biochem. Biophys. Res. Commun. 240, 84–87. 
Martinez-Mir M. I., Pollard H., Moreau J., Traiffort E., Ruat M., Schwartz J. C., Palacios J. M. (1993) 
Loss of striatal histamine H2 receptors in Huntington’s chorea but not in Parkinson's disease: 
Comparison with animal models. Synapse 15, 209–220. 
Marttila R. J., Lorentz H., Rinne U. K. (1988) Oxygen toxicity protecting enzymes in Parkinson’s 
disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. 
J. Neurol. Sci. 86, 321–331. 
Mash D. C., Pablo J., Buck B. E., Sanchez-Ramos J., Weiner W. J. (1991) Distribution and number of 
transferrin receptors in Parkinson’s disease and in MPTP-treated mice. Exp. Neurol. 114, 73–81. 
Mastroberardino P. G., Hoffman E. K., Horowitz M. P., Betarbet R., Taylor G., Cheng D., Na H. M., 
et al. (2009) A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted 
in Parkinson’s disease. Neurobiol. Dis. 34, 417–31. 
Mattila P., Röyttä M., Lönnberg P., Marjamäki P., Helenius H., Rinne J. O. (2001) Choline 
acetyltransferase activity and striatal dopamine receptors in Parkinson’s disease in relation to 
cognitive impairment. Acta Neuropathol 102, 160–166. 
McNaught K., Belizaire R., Isacson O., Jenner P., Olanow C. W. (2003) Altered Proteasomal Function 
in Sporadic Parkinson’s Disease. Exp. Neurol. 179, 38–46. 
McNaught K. S. P., Jenner P. (2001) Proteasomal function is impaired in substantia nigra in 
Parkinson’s disease. Neurosci. Lett. 297, 191–194. 
Michael G. J., Esmailzadeh S., Moran L. B., Christian L., Pearce R. K. B., Graeber M. B. (2011) Up-
regulation of metallothionein gene expression in parkinsonian astrocytes. Neurogenetics 12, 295–
305. 
Miki Y., Tanji K., Mori F., Utsumi J., Sasaki H., Kakita A., Takahashi H., Wakabayashi K. (2015) 
Alteration of upstream autophagy-related proteins (ULK1, ULK2, Beclin1, VPS34, and 
AMBRA1) in Lewy body disease. Brain Pathol. 
Miklossy J., Doudet D. D., Schwab C., Yu S., McGeer E. G., McGeer P. L. (2006) Role of ICAM-1 in 
persisting inflammation in Parkinson disease and MPTP monkeys. Exp. Neurol. 197, 275–83. 
Miller G. W., Erickson J. D., Perez J. T., Penland S. N., Mash D. C., Rye D. B., Levey A. I. (1999) 
Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson’s 
disease. Exp. Neurol. 156, 138–148. 
41 
 
Mirza B., Hadberg H., Thomsen P., Moos T. (1999) The absence of reactive astrocytosis is indicative 
of a unique inflammatory process in Parkinson’s disease. Neuroscience 95, 425–432. 
Mizuno Y., Matuda S., Yoshino H., Mori H., Hattori N., Ikebe S. (1994) An immunohistochemical 
study on alpha-ketoglutarate dehydrogenase complex in Parkinson’s disease. Ann. Neurol. 35, 
204–10. 
Mochizuki H., Goto K., Mori H., Mizuno Y. (1996) Histochemical detection of apoptosis in 
Parkinson’s disease. J. Neurol. Sci. 137, 120–123. 
Mogi M., Harada M., Kondo T., Mizuno Y., Narabayashi H., Riederer P., Nagatsu T. (1996a) The 
soluble form of Fas molecule is elevated in parkinsonian brain tissues. Neurosci. Lett. 220, 195–
198. 
Mogi M., Harada M., Kondo T., Narabayashi H., Riederer P., Nagatsu T. (1995) Transforming growth 
factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in 
Parkinson’s disease. Neurosci. Lett. 193, 129–132. 
Mogi M., Harada M., Kondo T., Riederer P., Inagaki H., Minami M., Nagatsu T. (1994a) Interleukin-1 
beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in 
the brain from parkinsonian patients. Neurosci. Lett. 180, 147–50. 
Mogi M., Harada M., Kondo T., Riederer P., Nagatsu T. (1996b) Interleukin-2 but not basic fibroblast 
growth factor is elevated in parkinsonian brain. J. Neural Transm. 103, 1077–81. 
Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T. (1994b) Tumor necrosis 
factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from 
parkinsonian patients. Neurosci. Lett. 165, 208–10. 
Mogi M., Kondo T., Mizuno Y., Nagatsu T. (2007) p53 protein, interferon-gamma, and NF-kappaB 
levels are elevated in the parkinsonian brain. Neurosci. Lett. 414, 94–7. 
Mogi M., Togari A., Kondo T., Mizuno Y., Kogure O., Kuno S., Ichinose H., Nagatsu T. (2001) Glial 
cell line-derived neurotrophic factor in the substantia nigra from control and parkinsonian brains. 
Neurosci. Lett. 300, 179–181. 
Mogi M., Togari A., Kondo T., Mizuno Y., Komure O., Kuno S., Ichinose H., Nagatsu T. (1999) 
Brain-derived growth factor and nerve growth factor concentrations are decreased in the 
substantia nigra in Parkinson’s disease. Neurosci. Lett. 270, 45–48. 
Mogi M., Togari A., Kondo T., Mizuno Y., Komure O., Kuno S., Ichinose H., Nagatsu T. (2000) 
Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia 
nigra from parkinsonian brain. J. Neural Transm. 107, 335–41. 
Moisoi N., Klupsch K., Fedele V., East P., Sharma S., Renton  a, Plun-Favreau H., et al. (2009) 
Mitochondrial dysfunction triggered by loss of HtrA2 results in the activation of a brain-specific 
transcriptional stress response. Cell Death Differ. 16, 449–64. 
Montis G. de, Beaumont K., Javoy-Agid F., Agid Y., Constandinidis J., Lowenthal A., Lloyd K. G. 
(1982) Glycine receptors in the human substantia nigra as defined by [3H]strychnine binding. J 
Neurochem 38, 718–724. 
Moos T., Jensen P. H. (2004) Absence of prostate apoptosis response-4 protein in substantia nigra of 
Parkinson’s disease autopsies. Acta Neuropathol. 107, 23–6. 
Morais V. A., Haddad D., Craessaerts K., Bock P.-J. De, Swerts J., Vilain S., Aerts L., et al. (2014) 
PINK1 loss-of-function mutations affect mitochondrial complex I activity via NdufA10 
ubiquinone uncoupling. Science 344, 203–7. 
Morgan M. J., Liu Z. (2011) Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res. 21, 
42 
 
103–115. 
Moroo I., Yamada T., Makino H., Tooyama I., McGreer P. L., McGeer E. G., Hirayama K. (1994) 
Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in 
Parkinson’s disease. 
Mouatt-Prigent A., Karlsson J. O., Agid Y., Hirsch E. C. (1996) Increased M-calpain expression in the 
mesencephalon of patients with Parkinson’s disease but not in other neurodegenerative disorders 
involving the mesencephalon: a role in nerve cell death? Neuroscience. 
Mouatt-Prigent A., Karlsson J. O., Yelnik J., Agid Y., Hirsch E. C. (2000) Calpastatin 
immunoreactivity in the monkey and human brain of control subjects and patients with 
Parkinson’s disease. J. Comp. Neurol. 419, 175–92. 
Muiswinkel F. L. van, Vos R. a I. de, Bol J. G. J. M., Andringa G., Jansen Steur E. N. H., Ross D., 
Siegel D., Drukarch B. (2004) Expression of NAD(P)H quinone oxidoreductase in the normal 
and Parkinsonian substantia nigra. Neurobiol. Aging 25, 1253–62. 
Muqit M. M. K., Abou-Sleiman P. M., Saurin A. T., Harvey K., Gandhi S., Deas E., Eaton S., et al. 
(2006) Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal 
stress. J. Neurochem. 98, 156–69. 
Murphy K. E., Gysbers A. M., Abbott S. K., Tayebi N., Kim W. S., Sidransky E., Cooper A., Garner 
B., Halliday G. M. (2014) Reduced glucocerebrosidase is associated with increased α-synuclein 
in sporadic Parkinson’s disease. Brain 137, 834–48. 
Mythri R. B., Venkateshappa C., Harish G., Mahadevan A., Muthane U. B., Yasha T. C., Srinivas 
Bharath M. M., Shankar S. K. (2011) Evaluation of markers of oxidative stress, antioxidant 
function and astrocytic proliferation in the striatum and frontal cortex of Parkinson’s disease 
brains. Neurochem. Res. 36, 1452–63. 
Nakabeppu Y., Tsuchimoto D., Yamaguchi H., Sakumi K. (2007) Oxidative Damage in Nucleic Acids 
and Parkinson’s Disease. J. Neurosci. Res. 934, 919–934. 
Nakamura A., Kitami T., Mori H., Mizuno Y., Hattori N. (2006) Nuclear localization of the 20S 
proteasome subunit in Parkinson’s disease. Neurosci. Lett. 406, 43–8. 
Navarro A., Boveris A., Bández M. J., Sánchez-Pino M. J., Gómez C., Muntané G., Ferrer I. (2009) 
Human brain cortex: mitochondrial oxidative damage and adaptive response in Parkinson disease 
and in dementia with Lewy bodies. Free Radic. Biol. Med. 46, 1574–80. 
Oakley A. E., Collingwood J. F., Dobson J., Love G., Perrott H. R., Edwardson J. A., Elstner M., 
Morris C. M. (2007) Individual dopaminergic neurons show raised iron levels in Parkinson 
disease. Neurology 68, 1820–5. 
Ordoñez C., Navarro A., Perez C., Astudillo A., Martínez E., Tolivia J. (2006) Apolipoprotein D 
expression in substantia nigra of Parkinson disease. Histol. Histopathol. 21, 361–366. 
Orr C. F., Rowe D. B., Mizuno Y., Mori H., Halliday G. M. (2005) A possible role for humoral 
immunity in the pathogenesis of Parkinson’s disease. Brain 128, 2665–74. 
Orsucci D., Caldarazzo Ienco E., Mancuso M., Siciliano G. (2011) POLG1-related and other 
“mitochondrial Parkinsonisms”: an overview. J. Mol. Neurosci. 44, 17–24. 
Ozawa T., Hayakawa M., Katsumata K., Yoneda M., Ikebe S., Mizuno Y. (1997) Fragile 
mitochondrial DNA: the missing link in the apoptotic neuronal cell death in Parkinson’s disease. 
Biochem. Biophys. Res. Commun. 235, 158–161. 
Parain K., Murer M. G., Yan Q., Faucheux B., Agid Y., Hirsch E., Raisman-Vozari R. (1999) Reduced 
expression of brain-derived neurotrophic factor protein in Parkinson’s disease substantia nigra. 
43 
 
Neuroreport 10, 557–561. 
Parker W. D., Parks J. K., Swerdlow R. H. (2008) Complex I deficiency in Parkinson’s disease frontal 
cortex. Brain Res. 1189, 215–218. 
Parsons R. B., Smith S. W., Waring R. H., Williams A. C., Ramsden D. B. (2003) High expression of 
nicotinamide N-methyltransferase in patients with idiopathic Parkinson’s disease. Neurosci. Lett. 
342, 13–16. 
Pearce R. K. B., Owen A., Daniel S., Jenner P., Marsden C. D. (1997) Alterations in the distribution of 
glutathione in the substantia nigra in Parkinson’s disease. J. Neural Transm. 104, 661–677. 
Pey P., Pearce R. K. B., Kalaitzakis M. E., Griffin W. S. T., Gentleman S. M. (2014) Phenotypic 
profile of alternative activation marker CD163 is different in Alzheimer’s and Parkinson's 
disease. Acta Neuropathol. Commun. 2, 21. 
Pickrell A. M., Youle R. J. (2015) The Roles of PINK1, Parkin, and Mitochondrial Fidelity in 
Parkinson’s Disease. Neuron 85, 257–273. 
Piggott M. A., Ballard C. G., Dickinson H. O., McKeith I. G., Perry R. H., Perry E. K. (2007) 
Thalamic D2 receptors in dementia with Lewy bodies, Parkinson’s disease, and Parkinson's 
disease dementia. Int. J. Neuropsychopharmacol. 10, 231–44. 
Piggott M. A., Marshall E. F., Thomas N., Lloyd S., Court J. A., Jaros E., Burn D., et al. (1999) 
Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer’s and Parkinson’s 
diseases : rostrocaudal distribution. Brain 122, 1449–1468. 
Plun-Favreau H., Klupsch K., Moisoi N., Gandhi S., Kjaer S., Frith D., Harvey K., et al. (2007) The 
mitochondrial protease HtrA2 is regulated by Parkinson’s disease-associated kinase PINK1. Nat. 
Cell Biol. 9, 1243–52. 
Polymeropoulos M. H., Lavedan C., Leroy E., Ide S. E., Dehejia A., Dutra A., Pike B., et al. (1997) 
Mutation in the α-Synuclein Gene Identified in Families with Parkinson’s Disease. Science 276, 
2045–2047. 
Power J. H. T., Shannon J. M., Blumbergs P. C., Gai W. (2002) Nonselenium glutathione peroxidase 
in human brain. Am. J. Pathol. 161, 885–894. 
Pranski E. L., Dalal N. V., Sanford C. Van, Herskowitz J. H., Gearing M., Lazo C., Miller G. W., Lah 
J. J., Levey A. I., Betarbet R. S. (2013) RING finger protein 11 (RNF11) modulates 
susceptibility to 6-OHDA-induced nigral degeneration and behavioral deficits through NF-KB 
signaling in dopaminergic cells. Neurobiol. Dis. 54, 264–279. 
Press P., Waeber C. (1989) Serotonin-1 receptor binding sites in the human basal ganglia are 
decreased in Huntington’s chorea but not in Parkinson's disease: a quantitative in vitro 
autoradiography study. Neuroscience 32, 337–347. 
Price D. L., Rockenstein E., Ubhi K., Phung V., MacLean-Lewis N., Askay D., Cartier A., et al. 
(2010) Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic 
models of alpha-synucleinopathy--implications for excitotoxicity. PLoS One 5, e14020. 
Qu D., Rashidian J., Mount M. P., Aleyasin H., Parsanejad M., Lira A., Haque E., et al. (2007) Role of 
Cdk5-mediated phosphorylation of Prx2 in MPTP toxicity and Parkinson’s disease. Neuron 55, 
37–52. 
Radunović A., Porto W. G., Zeman S., Leigh P. N. (1997) Increased mitochondrial superoxide 
dismutase activity in Parkinson’s disease but not amyotrophic lateral sclerosis motor cortex. 
Neurosci. Lett. 239, 105–8. 
Ramonet D., Podhajska A., Stafa K., Sonnay S., Trancikova A., Tsika E., Pletnikova O., Troncoso J. 
44 
 
C., Glauser L., Moore D. J. (2012) PARK9-associated ATP13A2 localizes to intracellular acidic 
vesicles and regulates cation homeostasis and neuronal integrity. Hum. Mol. Genet. 21, 1725–43. 
Ramsey C. P., Glass C. A., Montgomery M. B., Lindl K. A., Ritson G. P., Chia L. A., Hamilton R. L., 
Chu C. T., Jordan-Sciutto K. L. (2007) Expression of Nrf2 in neurodegenerative diseases. J. 
Neuropathol. Exp. Neurol. 66, 75–85. 
Reynolds A. D., Glanzer J. G., Kadiu I., Ricardo-Dukelow M., Chaudhuri A., Ciborowski P., Cerny 
R., et al. (2008) Nitrated alpha-synuclein-activated microglial profiling for Parkinson’s disease. 
J. Neurochem. 104, 1504–25. 
Riederer P., Sofic E., Rausch W. D., Schmidt B., Reynolds G. P., Jellinger K., Youdim M. B. (1989) 
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 
52, 515–20. 
Rieker C., Engblom D., Kreiner G., Domanskyi A., Schober A., Stotz S., Neumann M., et al. (2011) 
Nucleolar disruption in dopaminergic neurons leads to oxidative damage and parkinsonism 
through repression of mammalian target of rapamycin signaling. J. Neurosci. 31, 453–60. 
Rijk M. C. de, Launer L. J., Berger K., Breteler M. M., Dartigues J. F., Baldereschi M., Fratiglioni L., 
et al. (2000) Prevalence of Parkinson’s disease in Europe: A collaborative study of population-
based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54, S21–S23. 
Rinne J. O., Lnnberg P., Marjam P., Rinne U. K. (1989) Brain muscarinic receptor subtypes are 
differently affected in Alzheimer’s disease and Parkinson's disease. Brain Res. 483, 402–406. 
Rohn T. T., Catlin L. W. (2011) Immunolocalization of influenza A virus and markers of 
inflammation in the human Parkinson’s disease brain. PLoS One 6, e20495. 
Ros-Bernal F., Hunot S., Herrero M. T., Parnadeau S., Corvol J.-C., Lu L., Alvarez-Fischer D., et al. 
(2011) Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic 
neurodegeneration in parkinsonism. Proc. Natl. Acad. Sci. U. S. A. 108, 6632–7. 
Ross B. M., Mamalias N., Moszczynska A., Rajput A. H., Kish S. J. (2001) Elevated activity of 
phospholipid biosynthetic enzymes in substantia nigra of patients with Parkinson’s disease. 
Neuroscience 102, 7–12. 
Rothaug M., Zunke F., Mazzulli J. R., Schweizer M., Altmeppen H., Lüllmann-Rauch R., Kallemeijn 
W. W., et al. (2014) LIMP-2 expression is critical for β-glucocerebrosidase activity and α-
synuclein clearance. Proc. Natl. Acad. Sci. U. S. A. 111, 15573–8. 
Rott R., Szargel R., Haskin J., Bandopadhyay R., Lees A., Shani V., Engelender S. (2011) α-Synuclein 
fate is determined by USP9X-regulated monoubiquitination. Proc. Natl. Acad. Sci. 108, 18666–
71. 
Rousseau E., Michel P. P., Hirsch E. C. (2013) The iron-binding protein lactoferrin protects vulnerable 
dopamine neurons from degeneration by preserving mitochondrial calcium homeostasis. Mol. 
Pharmacol. 84, 888–98. 
Rubio de la Torre E., Luzón-Toro B., Forte-Lago I., Minguez-Castellanos A., Ferrer I., Hilfiker S. 
(2009) Combined kinase inhibition modulates parkin inactivation. Hum. Mol. Genet. 18, 809–23. 
Ryoo H. L., Dylan B. S., Bs P., Joyce J. N. (1998) Dopamine D3 Receptor is Decreased and D2 
Receptor is Elevated in the Striatum of Parkinson’s Disease. Isis 13, 788–797. 
Saito Y., Miyasaka T., Hatsuta H., Takahashi-Niki K., Hayashi K., Mita Y., Kusano-Arai O., et al. 
(2014) Immunostaining of oxidized DJ-1 in human and mouse brains. J. Neuropathol. Exp. 
Neurol. 73, 714–28. 
Salazar J., Mena N., Hunot S., Prigent A., Alvarez-Fischer D., Arredondo M., Duyckaerts C., et al. 
45 
 
(2008) Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models 
of Parkinson’s disease. Proc. Natl. Acad. Sci. U. S. A. 105, 18578–18583. 
Sanders L. H., McCoy J., Hu X., Mastroberardino P. G., Dickinson B. C., Chang C. J., Chu C. T., 
Houten B. Van, Greenamyre J. T. (2014) Mitochondrial DNA damage: Molecular marker of 
vulnerable nigral neurons in Parkinson’s disease. Neurobiol. Dis. 70, 214–223. 
Sathe K., Maetzler W., Lang J. D., Mounsey R. B., Fleckenstein C., Martin H. L., Schulte C., et al. 
(2012) S100B is increased in Parkinson’s disease and ablation protects against MPTP-induced 
toxicity through the RAGE and TNF-α pathway. Brain 135, 3336–47. 
Schapira A. H., Cooper J. M., Dexter D., Jenner P., Clark J. B., Marsden C. D. (1989) Mitochondrial 
complex I deficiency in Parkinson’s disease. Lancet 1, 1269. 
Schapira A. H., Mann V. M., Cooper J. M., Dexter D., Daniel S. E., Jenner P., Clark J. B., Marsden C. 
D. (1990) Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in 
Parkinson’s disease. J. Neurochem. 55, 2142–2145. 
Schipper H. M. (2004) Heme oxygenase expression in human central nervous system disorders. Free 
Radic. Biol. Med. 37, 1995–2011. 
Schipper H. M., Song W., Zukor H., Hascalovici J. R., Zeligman D. (2009) Heme oxygenase-1 and 
neurodegeneration: expanding frontiers of engagement. J. Neurochem. 110, 469–485. 
Schlossmacher M. G., Frosch M. P., Gai W. P., Medina M., Sharma N., Forno L., Ochiishi T., et al. 
(2002) Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. 
Am. J. Pathol. 160, 1655–1667. 
Schwab B. C., Heida T., Zhao Y., Gils S. a van, Wezel R. J. a van (2014) Pallidal gap junctions-
triggers of synchrony in Parkinson’s disease? Mov. Disord. 29, 1486–94. 
Seirafi M., Kozlov G., Gehring K. (2015) Parkin structure and function. FEBS J. 282, 2076–88. 
Shamoto-Nagai M., Maruyama W., Hashizume Y., Yoshida M., Osawa T., Riederer P., Naoi M. 
(2007) In parkinsonian substantia nigra, alpha-synuclein is modified by acrolein, a lipid-
peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome 
activity. J. Neural Transm. 114, 1559–67. 
Sharma M., Burre J., Sudhof T. C. (2012) Proteasome inhibition alleviates SNARE-dependent 
neurodegeneration. Sci. Transl. Med. 4, 147ra113. 
Sharon R., Bar-joseph I., Frosch M. P., Walsh D. M., Hamilton J. A., Selkoe D. J. (2003) The 
Formation of Highly Soluble Oligomers of alpha -Synuclein Is Regulated by Fatty Acids and 
Enhanced in Parkinson ’ s Disease. Neuron 37, 583–595. 
She H., Yang Q., Shepherd K., Smith Y., Miller G., Testa C., Mao Z. (2011) Direct regulation of 
complex I by mitochondrial MEF2D is disrupted in a mouse model of Parkinson disease and in 
human patients. J. Clin. Invest. 121, 930–940. 
Shehadeh L., Mitsi G., Adi N., Bishopric N., Papapetropoulos S. (2009) Expression of Lewy body 
protein septin 4 in postmortem brain of Parkinson’s disease and control subjects. Mov. Disord. 
24, 204–10. 
Shephard F., Greville-Heygate O., Marsh O., Anderson S., Chakrabarti L. (2014) A mitochondrial 
location for haemoglobins-Dynamic distribution in ageing and Parkinson’s disease. 
Mitochondrion 14, 64–72. 
Shimoda-Matsubayashi S., Hattori T., Matsumine H., Shinohara A., Yoritaka A., Mori H., Kondo T., 
Chiba M., Mizuno Y. (1997) Mn SOD activity and protein in a patient with chromosome 6-
linked autosomal recessive parkinsonism in comparison with Parkinson’s disease and control. 
46 
 
Neurology 49, 1257–62. 
Shimoji M., Pagan F., Healton E. B., Mocchetti I. (2009) CXCR4 and CXCL12 expression is 
increased in the nigro-striatal system of Parkinson’s disease. Neurotox. Res. 16, 318–28. 
Shimura-Miura H., Hattori N., Kang D., Miyako K., Nakabeppu Y., Mizuno Y. (1999) Increased 8-
oxo-dGTPase in the mitochondria of substantia nigral neurons in Parkinson’s disease. Ann. 
Neurol. 46, 920–4. 
Shin J.-H., Ko H. S., Kang H., Lee Y., Lee Y.-I., Pletinkova O., Troconso J. C., Dawson V. L., 
Dawson T. M. (2011) PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration 
in Parkinson’s disease. Cell 144, 689–702. 
Sian J., Dexter D. T., Lees  a J., Daniel S., Agid Y., Javoy-Agid F., Jenner P., Marsden C. D. (1994) 
Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders 
affecting basal ganglia. Ann. Neurol. 36, 348–355. 
Slodzinski H., Moran L. B., Michael G. J., Wang B., Novoselov S., Cheetham M. E., Graeber M. B. 
(2009) Homocysteine-induced endoplasmic reticulum protein (Herp) is up-regulated in 
parkinsonian substantia nigra and present in the core of Lewy bodies. Clin. Neuropathol. 28, 
333–343. 
Slone S. R., Lavalley N., McFerrin M., Wang B., Yacoubian T. A. (2015) Increased 14-3-3 
phosphorylation observed in Parkinson’s disease reduces neuroprotective potential of 14-3-3 
proteins. Neurobiol. Dis. 79, 1–13. 
Sofic E., Lange K. W., Jellinger K., Riederer P. (1992) Reduced and oxidized glutathione in the 
substantia nigra of patients with Parkinson’s disease. Neurosci. Lett. 142, 128–130. 
Soós J., Engelhardt J. I., Siklós L., Havas L., Majtényi K. (2004) The expression of PARP, NF-kappa 
B and parvalbumin is increased in Parkinson disease. Neuroreport 15, 1715–8. 
Spencer J. P., Jenner P., Daniel S. E., Lees A. J., Marsden D. C., Halliwell B. (1998) Conjugates of 
catecholamines with cysteine and GSH in Parkinson’s disease: possible mechanisms of 
formation involving reactive oxygen species. J. Neurochem. 71, 2112–22. 
Stanzione P., Tropepi D. (2011) Drugs and clinical trials in neurodegenerative diseases. Ann. Ist. 
Super. Sanita 47, 49–54. 
Steiner J. A., Angot E., Brundin P. (2011) A deadly spread: cellular mechanisms of α-synuclein 
transfer. Cell Death Differ. 18, 1425–1433. 
Sunico C. R., Nakamura T., Rockenstein E., Mante M., Adame A., Chan S. F., Newmeyer T. F., 
Masliah E., Nakanishi N., Lipton S. a (2013) S-Nitrosylation of parkin as a novel regulator of 
p53-mediated neuronal cell death in sporadic Parkinson’s disease. Mol. Neurodegener. 8, 29. 
Szegezdi E., Logue S. E., Gorman A. M., Samali A. (2006) Mediators of endoplasmic reticulum 
stress-induced apoptosis. EMBO Rep. 7, 880–885. 
Tanaka C., Nishino N., Hashimoto T., Kitamura N., Yoshihara C., Saito N. (1993) Second messenger 
systems in brains of patients with Parkinson’s or Huntington's disease. Adv. Neurol. 60, 175–80. 
Tanji K., Kamitani T., Mori F., Kakita A., Takahashi H., Wakabayashi K. (2010) TRIM9, a novel 
brain-specific E3 ubiquitin ligase, is repressed in the brain of Parkinson’s disease and dementia 
with Lewy bodies. Neurobiol. Dis. 38, 210–218. 
Tatton N. (2000) Increased caspase-3 and Bax immunoreactivity accompany nuclear GAPDH 
translocation and neuronal apoptosis in Parkinson’s disease. Exp. Neurol. 166, 29–43. 
Teismann P., Tieu K., Choi D., Wu D., Naini A., Hunot S., Vila M., Jackson-Lewis V., Przedborski S. 
(2003) Cyclooxygenase-2 is instrumental in Parkinson’s disease neurodegeneration. Proc. Natl. 
47 
 
Acad. Sci. U. S. A. 100, 5473–5478. 
Thibaut F., Faucheux B. A., Marquez J., Villares J., Menard J. F., Agid Y., Hirsch E. C. (1995) 
Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control 
subjects and patients with Parkinson’s disease: a postmortem study using tritiated tetrabenazine. 
Brain Res. 692, 233–243. 
Timmons S., Coakley M. F., Moloney A. M., O’ Neill C. (2009) Akt signal transduction dysfunction 
in Parkinson’s disease. Neurosci. Lett. 467, 30–5. 
Tofaris G. K., Kim H. T., Hourez R., Jung J.-W., Kim K. P., Goldberg A. L. (2011) Ubiquitin ligase 
Nedd4 promotes a-synuclein degradation by the endosomal-lysosomal pathway. Proc. Natl. 
Acad. Sci. 108, 17004–9. 
Tompkins M. M., Basgall E. J., Zamrini E., Hill W. D. (1997) Apoptotic-like changes in Lewy-body-
associated disorders and normal aging in substantia nigral neurons. Am. J. Pathol. 150, 119–131. 
Tong J., Ang L.-C., Williams B., Furukawa Y., Fitzmaurice P., Guttman M., Boileau I., Hornykiewicz 
O., Kish S. J. (2015) Low levels of astroglial markers in Parkinson’s disease: relationship to α-
synuclein accumulation. Neurobiol. Dis. 82, 243–253. 
Tooyama I., McGeer E. G., Kawamata T., Kimura H., McGeer P. L. (1994) Retention of basic 
fibroblast growth factor immunoreactivity in dopaminergic neurons of the substantia nigra during 
normal aging in humans contrasts with loss in Parkinson’s disease. Brain Res. 656, 165–168. 
Tsika E., Glauser L., Moser R., Fiser A., Daniel G., Sheerin U. M., Lees A., et al. (2014) Parkinson’s 
disease-linked mutations in VPS35 induce dopaminergic neurodegeneration. Hum. Mol. Genet. 
23, 4621–4638. 
Uhl G. R., Hackney G. O., Torchia M., Stranov V., Tourtellotte W. W., Whitehouse P. J., Tran V., 
Strittmatter S. (1986) Parkinson’s disease: nigral receptor changes support peptidergic role in 
nigrostriatal modulation. Ann. Neurol. 20, 194–203. 
Varani K., Vincenzi F., Tosi A., Gessi S., Casetta I., Granieri G., Fazio P., et al. (2010) A2A 
adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with 
motor symptoms in Parkinson’s disease. FASEB J. 24, 587–98. 
Villar-Menéndez I., Porta S., Buira S. P., Pereira-Veiga T., Díaz-Sánchez S., Albasanz J. L., Ferrer I., 
Martín M., Barrachina M. (2014) Increased striatal adenosine A2A receptor levels is an early 
event in Parkinson’s disease-related pathology and it is potentially regulated by miR-34b. 
Neurobiol. Dis. 69, 206–14. 
Vilotti S., Codrich M., Dal Ferro M., Pinto M., Ferrer I., Collavin L., Gustincich S., Zucchelli S. 
(2012) Parkinson’s disease DJ-1 L166P alters rRNA biogenesis by exclusion of TTRAP from the 
nucleolus and sequestration into cytoplasmic aggregates via TRAF6. PLoS One 7, e35051. 
Visanji N. P., Collingwood J. F., Finnegan M. E., Tandon A., House E., Hazrati L.-N. (2013) Iron 
deficiency in parkinsonism: region-specific iron dysregulation in Parkinson’s disease and 
multiple system atrophy. J. Parkinsons. Dis. 3, 523–37. 
Viswanath V., Wu Y., Boonplueang R., Chen S., Stevenson F. F., Yantiri F., Yang L., Beal M. F., 
Andersen J. K. (2001) Caspase-9 activation results in downstream caspase-8 activation and Bid 
cleavage in MPTP-induced Parkinson’s disease. J. Neurosci. 21, 9519–9528. 
Vroon A., Drukarch B., Bol J. G. J. M., Cras P., Brevé J. J. P., Allan S. M., Relton J. K., Hoogland P. 
V. J. M., Dam A.-M. Van (2007) Neuroinflammation in Parkinson’s patients and MPTP-treated 
mice is not restricted to the nigrostriatal system: microgliosis and differential expression of 
interleukin-1 receptors in the olfactory bulb. Exp. Gerontol. 42, 762–71. 
Wakabayashi K., Tanji K., Odagiri S., Miki Y., Mori F., Takahashi H. (2013) The Lewy body in 
48 
 
Parkinson’s disease and related neurodegenerative disorders. Mol. Neurobiol. 47, 495–508. 
Walker D. G., Beach T. G., Xu R., Lile J., Beck K. D., McGeer E. G., L. McGeer P. (1998a) 
Expression of the proto-oncogene Ret, a component of the GDNF receptor complex, persists in 
human substantia nigra neurons in Parkinson’s disease. Brain Res. 792, 207–17. 
Walker D. G., Terai K., Matsuo A., Beach T. G., McGeer E. G., McGeer P. L. (1998b) 
Immunohistochemical analyses of fibroblast growth factor receptor-1 in the human substantia 
nigra. Comparison between normal and Parkinson’s disease cases. Brain Res. 794, 181–7. 
Watson D. L., Carpenter C. L., Marks S. S., Greenberg D. A. (1988) Striatal calcium channel 
antagonist receptors in Huntington’s disease and Parkinson's disease. Ann. Neurol. 23, 303–305. 
Westerlund M., Belin A. C., Anvret A., Håkansson A., Nissbrandt H., Lind C., Sydow O., Olson L., 
Galter D. (2008) Cerebellar alpha-synuclein levels are decreased in Parkinson’s disease and do 
not correlate with SNCA polymorphisms associated with disease in a Swedish material. FASEB 
J. 22, 3509–14. 
Wilhelmus M. M. M., Bol J. G. J. M., Haastert E. S. Van, Rozemuller A. J. M., Bu G., Drukarch B., 
Hoozemans J. J. M. (2011a) Apolipoprotein E and LRP1 increase early in Parkinson’s disease 
pathogenesis. Am J Pathol 179, 2152–2156. 
Wilhelmus M. M. M., Verhaar R., Andringa G., Bol J. G. J. M., Cras P., Shan L., Hoozemans J. J. M., 
Drukarch B. (2011b) Presence of tissue transglutaminase in granular endoplasmic reticulum is 
characteristic of melanized neurons in Parkinson’s disease brain. Brain Pathol. 21, 130–9. 
Wills J., Jones J., Haggerty T., Duka V., Joyce J. N., Sidhu A. (2010) Elevated tauopathy and alpha-
synuclein pathology in postmortem Parkinson’s disease brains with and without dementia. Exp. 
Neurol. 225, 210–8. 
Wu H., Chen S., Ammar A.-B., Xu J., Wu Q., Pan K., Zhang J., Hong Y. (2014) Crosstalk between 
macroautophagy and chaperone-mediated autophagy: Implications for the treatment of 
neurological diseases. Mol. Neurobiol. 52, 1284–96. 
Xuereb J. H., Perry E. K., Candy J. M., Bonham J. R., Perry R. H., Marshall E. (1990) Parameters of 
cholinergic neurotransmission in the thalamus in Parkinson’s disease and Alzheimer's disease. J. 
Neurol. Sci. 99, 185–197. 
Yamada T., McGeer P. L., Baimbridge K. G., McGeer E. G. (1990) Relative sparing in Parkinson’s 
disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res. 526, 303–
307. 
Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E. R., Mizuno Y. (1996) 
Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. 
Natl. Acad. Sci. U. S. A. 93, 2696–2701. 
Zarow C., Lyness S. A., Mortimer J. A., Chui H. C. (2015) Neuronal loss is greater in the locus 
coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. 60, 
337–341. 
Zhang J., Montine T. J., Smith M. A., Siedlak S. L., Gu G., Robertson D., Perry G. (2002) The 
mitochondrial common deletion in Parkinson’s disease and related movement disorders. Park. 
Relat. Disord. 8, 165–170. 
Zhang X., Tang N., Hadden T. J., Rishi A. K. (2011) Akt, FoxO and regulation of apoptosis. Biochim. 
Biophys. Acta - Mol. Cell Res. 1813, 1978–1986. 
Zhou D., Zhan C., Zhong Q., Li S. (2013) Upregulation of sestrin-2 expression via P53 protects 
against 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity. J. Mol. Neurosci. 51, 967–75. 
49 
 
Zhou J., Shao Z., Kerkela R., Ichijo H., Muslin A. J., Pombo C., Force T. (2009) Serine 58 of 14-3-
3zeta is a molecular switch regulating ASK1 and oxidant stress-induced cell death. Mol. Cell. 
Biol. 29, 4167–4176. 
  
50 
 
Table 1. Neurotransmitters and neurotrophic factors changes observed in the human 
parkinsonian brain at the protein level. Legend: Am: Amygdala; Ca: Caudate nucleus; Cb: 
Cerebellum; Cb Cx: Cerebral cortex; Cg Cx: Cingulate cortex; Cg Gy: Cingulate gyrus; Fr 
Cx: Frontal cortex; Fr Gy: Frontal gyrus; GP: Globus pallidus; Hp: Hippocampus; LC: Locus 
coeruleus; NAcc: Nucleus accumbens; nb: number; NBM: Nucleus basalis of Meynard; Oc 
Cx: Occipital cortex; PPN: pedunculopontine nucleus; Pu: Putamen; SN: Substantia nigra; 
STN: Subthalmic nucleus; Str: Striatum; Th: Thalamus; Tp Cx: Temporal cortex. 
 
Table 2. PD-linked genes changes observed in the human parkinsonian brain at the 
protein level. Legend: see Table 1. 
 
Table 3. Calcium and transition metal-related proteins changes observed in the human 
parkinsonian brain. Legend: see Table 1. 
 
Table 4. Changes neuroinflammatory-related proteins observed in the human 
parkinsonian brain. Legend: see Table 1. 
 
Table 5. Changes in mitochondrial and oxidative stress-related proteins observed in the 
human parkinsonian brain. Legend: see Table 1. 
 
Table 6. Changes in ubiquitin proteasome system, lysosomal and autophagy proteins 
observed in the human parkinsonian brain. Legend: see Table 1. 
 
Table 7. Changes in apoptosis-related proteins observed in the human parkinsonian 
brain. Legend: see Table 1. 
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Table 8. Changes in transcription factors and transduction pathways observed in the 
human parkinsonian brain. Legend: see Table 1.  
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Table 1. Neurotransmitters and neurotrophic factors observed in the human 
parkinsonian brain at the protein level. Legend: Am: Amygadala; Ca: Caudate nucleus; 
Cb: Cerebellum; Cb Cx: Cerebral cortex; Cg Cx: Cingulate cortex; Cg Gy: Cingulate gyrus; 
Fr Cx: Frontal cortex; Fr Gy: Frontal gyrus; GP: Globus pallidus; Hp: Hippocampus; LC: 
Locus coeruleus; NAcc: Nucleus accumbens; nb: number; NBM: Nucleus basalis of Meynard; 
Oc Cx: Occipital cortex; PPN: pedunculopontine nucleus; Pu: Putamen; SN: Substantia nigra; 
STN: Subthalmic nucleus; Str: Striatum; Th: Thalamus; Tp Cx: Temporal cortex. 
 
Protein Ref Structure Observation in PD 
Neurotransmitters, transporters and receptors 
5-S-Cysteinyl-DOPA (Spencer et al. 1998) SN ↑ levels 
5-S-Cysteinyl-DOPA (Spencer et al. 1998) GP, Ca, Pu = levels 
5-S-Cysteinyl-
DOPAC 
(Spencer et al. 1998) SN ↑ levels 
5-S-Cysteinyl-
DOPAC 
(Spencer et al. 1998) GP, Ca, Pu = levels 
5-S-Cysteinyl-
Dopamine 
(Spencer et al. 1998) SN ↑ levels 
5-S-Cysteinyl-
Dopamine 
(Spencer et al. 1998) GP, Ca, Pu = levels 
A2A receptor (Varani et al. 2010) Pu ↑ level and density 
A2A receptor (Villar-Menéndez et al. 2014) Str 
↑ levels in medium 
spiny neurons 
AchE (Xuereb et al. 1990) Th = activity 
AchE (Xuereb et al. 1990) STN ↓ activity 
AchR (Griffiths et al. 1990) Ca, Pu, Tp Cx = density 
AchR (Griffiths et al. 1990) GP ↑ density 
AchR (Gotti et al. 2006) Str ↓ density 
AchR (nicotinic) (Court et al. 2000) Ca, Pu ↓ density 
AchR (nicotinic) (Xuereb et al. 1990) STN,Th, Tp Cx = density 
AchR (α2 subunit) (Gotti et al. 2006) Str, Tp Cx = levels 
AchR (α3 subunit) (Gotti et al. 2006) Str, Tp Cx = levels 
AchR (α4 subunit) (Gotti et al. 2006) Tp Cx = levels 
AchR (α4 subunit) (Gotti et al. 2006) Cb Cx, Str ↓ levels 
AchR (α5 subunit) (Gotti et al. 2006) Str, Tp Cx = levels 
AchR (α6 subunit) (Gotti et al. 2006) Tp Cx = levels 
AchR (α6 subunit) (Gotti et al. 2006) Str ↓ levels 
AchR (α7-subunit) (Burghaus et al. 2003) Cb Cx ↓ levels 
AchR (α7-subunit) (Banerjee et al. 2000) Tp Cx ↓ nb of neurons 
AchR (β2 subunit) (Gotti et al. 2006) Tp Cx = levels 
AchR (β2 subunit) (Gotti et al. 2006) Str ↓ levels 
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AchR (β3 subunit) (Gotti et al. 2006) Tp Cx = levels 
AchR (β3 subunit) (Gotti et al. 2006) Str ↓ levels 
AchR (β4 subunit) (Gotti et al. 2006) Str, Tp Cx = levels 
Angiotensin II 
receptor 
(Allen et al. 1992) Ca, Pu, SN ↓ levels 
Arginine vasopressin (Leake et al. 1991) Oc Cx, Tp Cx = levels 
Asparagine (Gerlach et al. 1996) 
Ca, Fr Cx, GP, Nacc, 
Pu, SN, STN, Th 
= levels 
Aspartate (Gerlach et al. 1996) 
Ca, Fr Cx, GP, Nacc, 
Pu, SN, STN, Th 
= levels 
Beta-arrestin (Price et al. 2010) Ca, Fr Cx, Hp ↑ cytosolic levels 
ChAT 
(Rinne et al. 1989),(Mattila et al. 2001), 
(Gotti et al. 2006) 
Fr Cx, Hp, NBM, pFr 
Cx, Tp Cx 
↓ activity 
ChAT (Xuereb et al. 1990), (Gotti et al. 2006) STN, Str, Th = activity 
CRH (Leake et al. 1991) Oc Cx, Tp Cx = levels 
D1R 
(Mattila et al. 2001),(Piggott et al. 
1999),(Griffiths et al. 1994), 
Ca, Nacc, Pu = levels and density 
D2R (Griffiths et al. 1994), (Varani et al. 2010) Ca, Pu = density 
D2R (Piggott et al. 2007) Th ↑ levels 
D2R (Mattila et al. 2001) Ca, Pu = levels 
D2R (Piggott et al. 1999) Ca, Nacc, Pu ↑ density 
D2R (Ahlskog et al. 1991) Pu ↓ density 
D3R (Piggott et al. 1999) Ca, Nacc, Pu = density 
DAT (Ryoo et al. 1998), (Güzey et al. 2012) Ca, Pu ↓ levels 
DOPAC (Gerlach et al. 1996) 
GP, STN, SN, Fr Cx, 
Th 
= levels 
DOPAC (Gerlach et al. 1996) Ca, Fr Cx, Nacc, Pu ↓ levels 
Dopamine (Gerlach et al. 1996) STN, Th, SN, = levels 
Dopamine (Gerlach et al. 1996) Ca, GP, Nacc, Pu ↓ levels 
EAAC1 (Duerson et al. 2009) SN = levels 
GABA (Gerlach et al. 1996) Str, Th ↓ levels 
GABA (Gerlach et al. 1996) 
Ca, GP, Nacc, Pu, 
SN, STN 
= levels 
GABA receptor (Lloyd et al. 1977) SN ↓ density 
GABA receptor (Lloyd et al. 1977) GP, Th = density 
GABAAR (Griffiths et al. 1994) Ca, GP, Pu ↓ density 
Glutamate (Gerlach et al. 1996) 
Ca, Fr Cx, GP, Nacc, 
Pu, SN, STN, Th 
= levels 
Glutamine (Gerlach et al. 1996) Ca, GP, Th ↑ levels 
Glutamine (Gerlach et al. 1996) 
Fr Cx, Nacc, Pu, SN, 
STN 
= levels 
Glycine receptor (de Montis et al. 1982) SN ↓ density 
Histamine-2 receptor (Martinez-Mir et al. 1993) Str = levels 
Histamine-3 receptor (Goodchild et al. 1999) 
Ca, Cx, GP, Nacc, Pu, 
SN 
= levels 
HVA (Gerlach et al. 1996) Ca, Nacc, Pu ↓ levels 
HVA (Gerlach et al. 1996) 
Fr Cx, GP, SN, STN, 
Th 
= levels 
MAO (Gargalidis-Moudanos et al. 1997) Pu = activity 
MAOB (Gargalidis-Moudanos et al. 1997) Cb Cx = activity 
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mGluR5 (Price et al. 2010) Ca, Fr Cx ↑ levels 
mGluR5 (Price et al. 2010) Hp = levels 
Muscarinic receptor (Ahlskog et al. 1991) Pu ↓ density 
Muscarinic receptor  (Griffiths et al. 1994) Pu ↑ density 
Muscarinic receptor  (Griffiths et al. 1994) Ca = density 
Muscarinic receptor 
M1 
(Rinne et al. 1989) Fr Cx, Hp, Tp Cx = levels 
Muscarinic receptor 
M2 
(Rinne et al. 1989) Fr Cx, Tp Cx ↑ levels 
Muscarinic receptor 
M2 
(Rinne et al. 1989) Hp = levels 
Neuromelanin (Halliday et al. 2006) SN 
↑ levels in TH 
neurons 
Neurotensin receptor (Uhl et al. 1986) Mb ↓ density 
NMDA Receptor (Gerlach et al. 1996) Ca ↓ density 
NMDA Receptor (Gerlach et al. 1996) 
Fr Cx, GP, Nacc, Pu, 
SN, STN, Th 
= density 
NQO1 (van Muiswinkel et al. 2004) SN 
↑ levels in neurons 
and astrocytes 
Opiate receptor (µ) (Uhl et al. 1986) Mb ↓ density 
Opiate receptor (κ) (Uhl et al. 1986) Mb ↓ density 
Serotonin transporter (Güzey et al. 2012) Ca, Cg Gy ↓ density 
Serotonin-1 receptor (Press and Waeber 1989) Cx, Nacc, SN = density 
Somatostatin (Leake et al. 1991) Oc Cx, Tp Cx = levels 
Somatostatin receptor (Uhl et al. 1986) Mb ↓ density 
TH (Kastner et al. 1993) SN ↓ level per neuron 
TH (Ryoo et al. 1998) Pu ↓ levels 
TH (Ryoo et al. 1998) Ca, GP = levels 
VMAT2 (Thibaut et al. 1995) LC, Ra, SN ↓ density 
VMAT2 (Miller et al. 1999) Ca, Nacc, Pu ↓ levels 
Neurotrophic factors 
BDNF (Chauhan et al. 2001),(Mogi et al. 1999) Str, SN ↓ levels 
BDNF (Mogi et al. 1999) Cb, Fr Cx = levels 
BDNF (Imamura et al. 2005) Hp ↓ levels 
BDNF (Parain et al. 1999) SN 
↓ nb of expressing 
TH neurons 
BDNF (Knott et al. 2002) SN 
= levels in TH 
neurons  
BDNF (Knott et al. 2002) SN 
↑ nb of expressing 
astrocytes 
bFGF (Tooyama et al. 1994) SN 
↓ nb of expressing 
TH neurons 
bFGF (Mogi et al. 1996b) Ca, Cx, Pu = levels 
CNTF (Chauhan et al. 2001) SN ↓ levels 
CRH (Hoogendijk et al. 1998) PVN 
= nb of expressing 
neurons 
EGF (Mogi et al. 1999) Ca ↑ levels 
EGF (Mogi et al. 1999) Cb Cx, Pu = levels 
EGF (Iwakura et al. 2005) pFr Cx, Str ↓ levels 
ErbB1 (Iwakura et al. 2005) pFr Cx, Str ↓ levels 
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ErbB2 (Iwakura et al. 2005) pFr Cx, Str ↓ levels 
ErbB3 (Iwakura et al. 2005) pFr Cx, Str = levels 
ErbB4 (Iwakura et al. 2005) pFr Cx, Str = levels 
ErbB4 (Depboylu et al. 2012) SN 
↑ proportion of 
expressing TH 
neurons 
FGFR1 (Walker et al. 1998b) SN 
= levels in TH 
neurons 
GDNF (Mogi et al. 2001),(Chauhan et al. 2001) Pu, SN ↓ levels 
GDNF (Mogi et al. 2001) Ca ↑ levels 
GDNF (Mogi et al. 2001) Cb, Fr Cx = levels 
HB-EGF (Iwakura et al. 2005) pFr Cx, Str = levels 
Insulin receptor (Moroo et al. 1994) PPN, SN ↓ levels 
NGF (Mogi et al. 1999) SN ↓ levels 
NGF (Chauhan et al. 2001) SN = levels 
NT-3 (Chauhan et al. 2001),(Knott et al. 2002) SN, Str = levels 
NT-4 (Chauhan et al. 2001) SN = levels 
Ret (Decressac et al. 2012) SN 
↓ levels in TH 
neurons 
Ret (Walker et al. 1998a) SN = levels 
TGFα (Mogi et al. 1995) Ca, Pu ↑ levels 
TGFα (Iwakura et al. 2005),(Mogi et al. 1995) Cb Cx, pFr Cx, Str = levels 
TGF-β1 (Mogi et al. 1995) Ca, Pu ↑ levels 
TGF-β1 (Mogi et al. 1995) Cb Cx = levels 
TrkB (Knott et al. 2002) SN, Str = levels 
TrkC (Knott et al. 2002) SN, Str = levels 
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Table 2. PD-linked genes changes observed in the human parkinsonian brain at the protein level. 
Legend: see Table 1. 
 
Protein Ref Structure Observation in PD 
AF6 (Haskin et al. 2013) Str, SN ↓ levels 
AIMP2 (Imam et al. 2011),(Ko et al. 2010) SN, Str ↑ levels 
c-Abl (Mahul-Mellier et al. 2014) Cg Cx ↑ levels 
c-Abl (phosphorylated at 
Y245) 
(Imam et al. 2011),(Ko et al. 2010) Str ↑ levels 
c-Abl (phosphorylated at 
Y245) 
(Imam et al. 2011),(Ko et al. 2010) Cx, SN = levels 
DJ-1 (Bandopadhyay et al. 2004) Fr Cx = levels 
DJ-1 (oxidized) (Saito et al. 2014) Str, SN ↑ levels  
DJ-1 (S-nitrosylated)/ DJ-1 
(total) 
(Choi et al. 2014) Fr Cx ↓ ratio  
Dnmt1 (cytoplasm) (Desplats et al. 2011) Cx ↑ levels 
Dnmt1 (nuclear) (Desplats et al. 2011) Cx ↓ levels 
FBP1 (Imam et al. 2011),(Ko et al. 2010) SN, Str ↑ levels 
GRK5 (Arawaka et al. 2006) SN = levels 
Jtv-1 (Kurup et al. 2015) Str ↑ levels 
LRRK2 (Guerreiro et al. 2013) 
Ag, Cg Cx, Fr 
Cx 
↑ levels 
MMP3 (Choi et al. 2011) SN ↑ levels 
NAC1 (Korutla et al. 2014) SN 
aggregates with parkin in 
TH neurons 
Parkin (aggregated) (LaVoie et al. 2005) Ca, Pu ↑ levels 
Parkin (phosphorylated at 
S101) 
(Rubio de la Torre et al. 2009) Ca ↑ levels 
Parkin (phosphorylated at 
S101) 
(Rubio de la Torre et al. 2009) Cb, Cx = levels 
Parkin (S-nitrosylated) (Chung et al. 2004) 
Cg Cx, SN, Tp 
Cx 
↑ levels 
Parkin (soluble) (Lonskaya et al. 2013) Str ↓ level 
Parkin (total) 
(Wills et al. 2010),(Rubio de la 
Torre et al. 2009),(LaVoie et al. 
2005) 
Ca, Cb, Cx, Fr 
Gy, Str 
= levels 
Parkin (tyrosine-
phosphorylated) 
(Imam et al. 2011),(Ko et al. 2010) SN, Str ↑ levels 
PARIS (Shin et al. 2011) SN, Str ↑ levels 
PDCD2-1 (Fukae et al. 2009) Mb ↑ levels 
PINK1 (Muqit et al. 2006) Cb, SN ↑ levels 
PINK1 (Muqit et al. 2006) Cx = levels 
SEPT4 (Shehadeh et al. 2009) Ag, SN ↑ levels 
SMG1 (Henderson-Smith et al. 2013) Cg Cx ↓ levels 
STEP61 (Kurup et al. 2015) Str ↑ levels 
Tissue transglutaminase 
(Wilhelmus et al. 2011b),(Citron et 
al. 2002),(Andringa et al. 2004) 
SN 
↑ levels and activity, levels 
in TH neurons, nb of 
expressing TH neurons 
UCHL-1 (Barrachina et al. 2006) SN ↓ levels 
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UCHL-1 (Barrachina et al. 2006) Fr Cx = levels 
USP9X (Rott et al. 2011) SN ↓ levels 
VPS35 (Tsika et al. 2014) Ca, Pu, Fr Cx = levels 
α-synuclein (calpain-
cleaved) 
(Dufty et al. 2007) SN ↑ levels 
α-synuclein 
(dimer/monomer) 
(Sharon et al. 2003) SN ↑ ratio 
α-synuclein (insoluble) (Wills et al. 2010) Fr Gy, Str ↑ levels 
α-synuclein (mitochondria) (Devi et al. 2008) SN, Str ↑ levels 
α-synuclein (modified with 
acrolein) 
(Shamoto-Nagai et al. 2007) SN ↑ levels 
α-synuclein (nitrated) (Giasson et al. 2000) Cg Cx, Am ↑ levels 
α-synuclein 
(phosphorylated at S129) 
(Mahul-Mellier et al. 2014) Cg Cx ↑ levels 
α-synuclein 
(phosphorylated at Y125) 
(Mahul-Mellier et al. 2014) Cg Cx = levels 
α-synuclein 
(phosphorylated at Y39) 
(Mahul-Mellier et al. 2014) Cg Cx = levels 
α-synuclein (soluble) (Wills et al. 2010) Fr Gy, Str ↑ levels 
α-synuclein (total) (Westerlund et al. 2008) Cb ↓ levels 
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Table 3. Calcium and transition metal-related proteins changes observed in the human 
parkinsonian brain. Legend: see Table 1. 
 
Protein or metal Ref Structure Observation in PD 
Transition metals 
Al (Total) (Good et al. 1992) SN 
↑ levels in TH 
neurons 
Al (Total) (Hirsch et al. 1991) SN ↑ levels 
Ceruloplasmin (Loeffler et al. 2006) Hp ↑ levels 
Ceruloplasmin (Loeffler et al. 2006) Fr Cx ↓ levels 
Ceruloplasmin (Ayton et al. 2013) SN ↓ ferroxidase activity 
Ceruloplasmin (Ayton et al. 2013), (Loeffler et al. 2006) 
Ca, Cb, Fr Cx, 
Pu, SN 
= levels 
Ceruloplasmin (Ayton et al. 2013) Fr Cx = activity 
CTR1 (Davies et al. 2014) SN ↓ levels 
Cu (Total) (Riederer et al. 1989) Rp ↑ levels 
Cu (Total) (Dexter et al. 1989),(Ayton et al. 2013) SN ↓ levels 
Cu (Total) 
(Dexter et al. 1989),(Ayton et al. 
2013),(Riederer et al. 1989) 
Ca, Cb, Cx, Fr 
Cx, GP,  Pu, SN 
= levels 
DMT1 (Salazar et al. 2008) SN 
↑ levels in TH 
neurons 
Fe (Total) 
(Oakley et al. 2007),(Jellinger et al. 
1992),(Good et al. 1992) 
SN 
↑ levels in TH 
neurons 
Fe (Total) 
(Dexter et al. 1989),(Ayton et al. 
2013),(Hirsch et al. 1991),(Riederer et al. 
1989) 
SN ↑ levels 
Fe (Total) (Dexter et al. 1989) GP ↓ levels 
Fe (Total) 
(Dexter et al. 1989),(Ayton et al. 
2013),(Riederer et al. 1989) 
Ca, Cb, Cx, GP, 
Hp, Pu 
= levels 
Fe2+ (Riederer et al. 1989) 
Cx, GP, Hp, Pu, 
SN 
= levels 
Fe3+ (Riederer et al. 1989) SN ↑ levels 
Fe3+ (Riederer et al. 1989) Cx, GP, Hp, Pu = levels 
Ferritin (Riederer et al. 1989) SN ↑ levels 
Ferritin (Riederer et al. 1989) Pu = levels 
Ferritin (H-
Chain) 
(Galazka-Friedman et al. 2004) SN = levels 
Ferritin (L-
Chain) 
(Galazka-Friedman et al. 2004) SN ↓ levels 
Ferroportin (Visanji et al. 2013) SN ↑ levels 
Lactoferrin 
(Rousseau et al. 2013),(Leveugle et al. 
1996) 
SN 
↑ levels in TH 
neurons 
Lactoferrin 
receptor 
(Faucheux et al. 1995) SN 
↑ levels in TH 
neurons 
Metallothionein 
1 and 2 
(Michael et al. 2011) SN 
↑ nb of expressing 
astrocytes  
Mg (Total) (Riederer et al. 1989) 
Ca, GP, Pu, Rp, 
SN 
= levels 
Mn (Total) (Dexter et al. 1989) Pu ↓ levels 
Mn (Total) (Dexter et al. 1989) 
Ca, Cb, Cx, GP, 
SN 
= levels 
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NDFIP1 (Howitt et al. 2014) SN ↑ levels 
Pb (Total) (Dexter et al. 1989) 
Ca, Cb, Cx, GP, 
Pu, SN 
= levels 
Transferrin (Mastroberardino et al. 2009) SN ↑ levels 
Transferrin (Faucheux et al. 1997) SN 
↓ levels in TH 
neurons 
Transferrin 
receptor 
(Mash et al. 1991) Pu ↓ levels 
Transferrin 
receptor 
(Mash et al. 1991) Ca, GP = levels 
Zn (Total) (Dexter et al. 1989),(Riederer et al. 1989) Ca, Pu, Rp, SN ↑ levels 
Zn (Total) (Dexter et al. 1989),(Riederer et al. 1989) 
Ca, Cb, Cx, GP, 
Pu, SN 
= levels 
    
 
Calcium and calcium-binding proteins 
Ca2+ (Total) (Riederer et al. 1989) 
Ca, GP, Pu, Rp, 
SN 
= levels 
Calbindin (Hurley et al. 2013) NBM, SN 
↓ nb of expressing 
cells 
Calbindin (Hurley et al. 2013) Cb Cx, LC = levels 
Calcium 
channels 
(Watson et al. 1988) Str = levels 
Calmodulin (Hurley et al. 2013),(Reynolds et al. 2008) Cb Cx, LC, SN 
↓ nb of expressing 
cells 
Calmodulin (Hurley et al. 2013) NuBa = levels 
Calpain II (Mouatt-Prigent et al. 1996) LC, SN 
↑ nb of expressing 
neurons 
Calpastatin (Mouatt-Prigent et al. 2000) SN ↓ nb TH neurons 
Calreticulin (Hurley et al. 2013) LC, NBM, SN 
↓ nb of expressing 
cells 
Calreticulin (Hurley et al. 2013) Cb Cx = levels 
Calreticulin (Wilhelmus et al. 2011b) SN 
↑ levels in TH 
neurons 
Cav1.2 (Hurley et al. 2013) LC, NBM, SN 
↓ nb of expressing 
cells 
Cav1.2 (Hurley et al. 2013) Cb Cx = levels 
Cav1.3 (Hurley et al. 2013) Cb Cx, LC 
↑ nb of expressing 
cells 
Cav1.3 (Hurley et al. 2013) NBM, SN 
↓ nb of expressing 
cells 
Lipocortin-1 (Knott et al. 2000) SN 
↑ levels in microglial 
cells 
Parvalbumin (Soós et al. 2004) SN 
↑ levels in TH 
neurons 
PKC (Tanaka et al. 1993) SN ↓ levels 
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Table 4. Changes in neuroinflammatory-related proteins observed in the human parkinsonian 
brain. Legend: see Table 1. 
 
Protein Ref Structure Observation in PD 
C1q+ microglia (Depboylu et al. 2011) SN ↑ nb 
C9 (Loeffler et al. 2006) SN = levels 
Caspase-3 (activated) (Burguillos et al. 2011) SN ↑ levels in microglia 
Caspase-8 (activated) (Burguillos et al. 2011) SN ↑ levels in microglia 
CCL5 (Shimoji et al. 2009) Str ↓ levels 
CCL5 (Shimoji et al. 2009) Fr Cx, SN = levels 
CD163 (Pey et al. 2014) LC, SN 
↑ nb of expressing 
microglia 
CD23 (Hunot et al. 1999) SN ↑ levels 
CD23 (Hunot et al. 1999) SN 
↑ nb of expressing 
microglia 
CD23 (Hunot et al. 1999) SN 
↑ nb of expressing 
astrocyte 
CD68+ microglia (Vroon et al. 2007) OB ↑ nb 
CD4+ T cells (Brochard et al. 2009) SN ↑ nb 
CD8+ T cells (Brochard et al. 2009) SN ↑ nb 
CR3/43+ microglia 
(Imamura et al. 2003),(Imamura et al. 
2005),(Orr et al. 2005) 
Cg Cx, Hp, 
Pu,SN 
↑ nb 
CXCL12 (Shimoji et al. 2009) Str ↑ levels 
CXCL12 (Shimoji et al. 2009) Fr Cx, SN = levels 
CXCR4 (Shimoji et al. 2009) SN, Str ↑ levels 
CXCR4 (Shimoji et al. 2009) LC = levels 
Cyclooxygenase-2 (Teismann et al. 2003) SN ↑ levels in TH neurons 
Cyclooxygenase-2 (Teismann et al. 2003) SN ↑ levels 
GFAP 
(Lastres-Becker et al. 2012),(Mythri 
et al. 2011) 
Ca, Fr Cx, SN ↑ levels 
GFAP (Mythri et al. 2011) Pu = levels 
Glucocorticoid receptors (Ros-Bernal et al. 2011) Pu ↑ levels 
HO-1 (Schipper et al. 2009) SN 
↑ nb of expressing 
astrocytes 
Iba1 (Lastres-Becker et al. 2012) SN ↑ levels 
iC3b (Loeffler et al. 2006) SN 
↑ nb of expressing TH 
cells 
ICAM-1+astrocytes (Miklossy et al. 2006) SN ↑ nb 
ICAM-1+ microglia  (Imamura et al. 2003) Hp, Pu, SN ↑ nb 
IgG (Orr et al. 2005) SN ↑ levels in TH neurons 
IL-1β (Mogi et al. 1994a) Ca, Pu ↑ levels 
IL-1β (Mogi et al. 1994a) Cb Cx = levels 
IL-1β (Hunot et al. 1999) SN 
↑ nb of expressing glial 
cells 
IL-2 (Mogi et al. 1996b) Ca, Pu ↑ levels 
IL-2 (Mogi et al. 1996b) Cx = levels 
IL-6 (Mogi et al. 1994a) Ca, Pu ↑ levels 
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IL-6 (Mogi et al. 1994a) Cb Cx = levels 
iNOS (Knott et al. 2000) SN ↑ levels in glial cells 
Interferon ɣ (Hunot et al. 1999) SN 
↑ nb of expressing glial 
cells 
Interferon-ɣ (Mogi et al. 2007) Ca, Pu, SN ↑ levels 
Interferon-ɣ (Mogi et al. 2007) Cb, Fr Cx = levels 
Interferon-ɣ receptor (Hashioka et al. 2009) SN ↑ levels in astrocytes 
Ki-M1p+ microglia (Imamura et al. 2005) SN ↑ nb 
LFA-1+ leukocyte (Miklossy et al. 2006) SN ↑ nb 
LFA-1+ microglia (Miklossy et al. 2006) SN ↑ nb 
Lipocortin-1 (Knott et al. 2000) SN 
↑ levels in microglial 
cells 
MFGE8 (Kinugawa et al. 2013) SN 
↑ expression in 
astrocytes 
Myeloperoxidase (Choi et al. 2005a) SN ↑ levels in astrocytes 
NF-κB (nuclear) (Soós et al. 2004) SN 
↑ levels in TH neurons 
nuclei 
NOS (Hunot et al. 1996) SN, VTA 
↑ nb of expressing glial 
cells 
NOS  (Hunot et al. 1996) SN, VTA 
↓ nb of expressing 
neurons 
RAGE (Sathe et al. 2012) Mb = levels 
S100B (Sathe et al. 2012) Mb ↑ levels in astrocytes 
TNF-α (Hunot et al. 1999) SN 
↑ nb of expressing glial 
cells 
TNF-α (Mogi et al. 1994b) Ca, Str ↑ levels 
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Table 5. Changes in mitochondrial and oxidative stress-related proteins observed in the human 
parkinsonian brain. Legend: see Table 1. 
 
Protein Ref Structure Observation in PD 
Mitochondrial abnormalities and energy deficit 
6PGD (Dunn et al. 2014) Cx, Pu ↓ levels and activity 
AF6 (Haskin et al. 2013) SN, Str ↓ levels 
ATP synthase (Ferrer et al. 2007) SN ↓ levels 
ATP synthase (Ferrer et al. 2007) Fr Cx ↑ levels 
Citrate synthase (Schapira et al. 1990) 
Ca, Cb, Cr Cx, 
GP, SN 
= activity 
Complex I (Moisoi et al. 2009) Mb ↓ levels 
Complex I (Keeney et al. 2006) Fr Cx = levels 
Complex I (Hattori et al. 1993) SN 
↓ nb of expressing 
neurons 
Complex I 
(Navarro et al. 2009),(Schapira et al. 
1990),(Schapira et al. 1989),(Keeney et 
al. 2006),(Parker et al. 2008) 
Fr Cx, SN ↓ activity 
Complex I  (Mythri et al. 2011),(Schapira et al. 1990) 
Ca, Cb, Cr Cx, 
Fr Cx, GP, Pu 
= activity 
Complex I 
(carbonylated) 
(Keeney et al. 2006) Fr Cx ↑ levels 
Complex II (Moisoi et al. 2009) Mb ↓ levels 
Complex II (Keeney et al. 2006) Fr Cx = levels 
Complex II (Navarro et al. 2009),(Parker et al. 2008) Fr Cx = activity 
Complex III (Keeney et al. 2006) Fr Cx = levels 
Complex III (Schapira et al. 1990),(Parker et al. 2008) 
Ca, Cb, Cr Cx, 
Fr Cx, GP, SN 
= activity 
Complex III (Moisoi et al. 2009) Mb ↓ levels 
Complex IV (Moisoi et al. 2009),(Itoh et al. 1997) Mb, SN ↓ levels 
Complex IV (Keeney et al. 2006) Fr Cx = levels 
Complex IV 
(Navarro et al. 2009),(Schapira et al. 
1990),(Parker et al. 2008) 
Ca, Cb, Cr Cx, 
Fr Cx, GP, SN 
= activity 
Complex V (Keeney et al. 2006) Fr Cx = levels 
Complex V α (Moisoi et al. 2009) Mb ↓ levels 
Cytochrome a (Navarro et al. 2009) Fr Cx = levels 
Cytochrome b (Navarro et al. 2009) Fr Cx ↑ levels 
Cytochrome c (Navarro et al. 2009) Fr Cx ↑ levels 
DNA damage 
(mitochondria) 
(Sanders et al. 2014) SN ↑ nb in TH neurons 
DNA deletion 
(mitochondria) 
(Bender et al. 2006) SN ↑ levels 
DNA deletion 
(mitochondria) 
(Bender et al. 2006) Hp = levels 
DNA mutation 
(mitochondria) 
(Lin et al. 2013) SN ↑ nb in neurons 
G6PD (Dunn et al. 2014) Cx, Pu ↓ levels and activity 
Hemoglobin (alpha and 
beta) 
(Shephard et al. 2014) SN ↓ levels  
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HtrA2 (P-S142) (Plun-Favreau et al. 2007) Ca ↑ levels 
mitochondrial 
oxidative damage  
(Navarro et al. 2009) Fr Cx ↑ levels 
mitochondrial oxygen 
uptake 
(Navarro et al. 2009) Fr Cx ↓ levels 
NADPH production (Dunn et al. 2014) Cx, Pu ↑ levels 
ND6 (She et al. 2011) Str ↓ mitochondrial levels 
Nicotinamide N-
methyltransferase 
(Parsons et al. 2003) Ca, Cb ↑ levels and activity 
NOS (mitochondrial) (Navarro et al. 2009) Fr Cx ↑ activity 
oxygen uptake (Navarro et al. 2009) Fr Cx ↓ levels 
Prohibitin (Ferrer et al. 2007) SN ↓ levels 
Prohibitin (Ferrer et al. 2007) Fr Cx ↑ levels 
TOM20 (Bender et al. 2013) Mb = levels 
TOM40 (Bender et al. 2013) Mb ↓ levels 
VDAC1 (Chu et al. 2014) SN 
↓ nb of expressing TH 
neurons 
α-ketoglutarate 
dehydrogenase 
(Mizuno et al. 1994) SN ↓ levels 
Oxidative stress 
4-hydroxynonenal (Yoritaka et al. 1996) SN ↑ nb of reactive cells 
Ascorbic acid (total) (Riederer et al. 1989) 
Ca, GP, Pu, Ra, 
SN 
= levels 
ATM (phosphorylated 
at S1981) 
(Camins et al. 2010) Cg Cx ↑ levels 
Biliverdin reductase (Reynolds et al. 2008) SN ↑ levels 
Catalase (Ambani et al. 1975) SN, Str ↓ activity 
Catalase (Mythri et al. 2011) Ca, Fr Cx, Pu = activity 
Creatine kinase (Aksenova et al. 1999) Fr Cx = activity 
DNA polymerase δ (Camins et al. 2010) Cg Cx ↑ levels 
ɣ-glutamyl cysteine 
ligase (ɣ-GCL) 
(Mythri et al. 2011) Ca, Fr Cx, Pu = activity 
ɣ-glutamyl 
transpeptidase (ɣGT) 
(Mythri et al. 2011) Ca, Fr Cx, Pu ↓ activity 
ɣ-glutamylcysteine 
synthetase 
(Sian et al. 1994) 
Ca, Cr Cx, GP, 
Pu, SN 
= activity 
ɣ-
glutamyltranspeptidase 
(Sian et al. 1994) 
Ca, Cr Cx, GP, 
Pu, SN 
= activity 
ɣ-H2AX 
(phosphorylated) 
(Camins et al. 2010) Cg Cx ↑ levels 
Glutathione (oxidized) (Sian et al. 1994) Cr Cx, Pu, SN = levels 
Glutathione (oxidized) (Sofic et al. 1992) SN ↓ levels 
Glutathione (reduced) (Pearce et al. 1997) SN ↓ levels in TH neurons 
Glutathione (reduced) (Sian et al. 1994) SN ↓ levels 
Glutathione (reduced) (Sian et al. 1994) Cr Cx, Pu, SN = levels 
Glutathione (reduced) (Mythri et al. 2011) Ca, Fr Cx, Pu ↑ activity 
Glutathione Peroxidase 
(GPx) 
(Power et al. 2002) Fr Cx 
↑ nb of expressing 
astrocytes 
Glutathione Peroxidase 
(GPx) 
(Mythri et al. 2011),(Sian et al. 1994) 
Ca, Cr Cx, Fr 
Cx, GP, Pu, SN 
= activity 
Glutathione Peroxidase 
(GPx) 
(Mythri et al. 2011) Ca, Pu ↑ activity 
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Glutathione Peroxidase 
(GPx) 
(Power et al. 2002) Cg Gy, Fr Gy ↑ levels in microglia 
Glutathione reductase 
(GR) 
(Mythri et al. 2011) Ca, Fr Cx, Pu = activity 
Glutathione-S-
tranferase (GST) 
(Mythri et al. 2011) Ca, Fr Cx, Pu = activity 
Glutathione-S-
tranferase (GST) 
(Reynolds et al. 2008) SN ↓ levels  
Gluthatione transferase (Sian et al. 1994) 
Ca, Cr Cx, GP, 
Pu, SN 
= activity 
HO1 (Schipper 2004) SN 
↑ nb of expressing 
astrocytes 
HO1 (Lastres-Becker et al. 2012) SN ↑ levels 
Lipid peroxydation (Mythri et al. 2011) Fr Cx ↑ levels 
Lipid peroxydation (Mythri et al. 2011) Ca, Pu ↓ levels 
Mitochondrial 
oxidative damage 
(Navarro et al. 2009) Fr Cx ↑ levels 
Mitochondrial proteins (Navarro et al. 2009) Fr Cx ↑ levels 
MTH1 (Nakabeppu et al. 2007) SN ↑ levels 
MTH1 (Shimura-Miura et al. 1999) SN ↑ levels in mitochondria 
MUTYH (Nakabeppu et al. 2007) SN ↑ levels 
MUTYH (Arai et al. 2006) SN ↑ levels in TH neurons 
NOX1 (Choi et al. 2012) SN ↑ nb of TH neurons  
NQO1 (NADPH 
quinone 
oxidoreductase) 
(van Muiswinkel et al. 2004) SN 
↑ levels in neurons and 
astrocytes 
Nrf2 (Ramsey et al. 2007) SN 
↑ nuclear and 
↓cytoplasmic levels 
Nucleolar integrity (Rieker et al. 2011) SN ↓levels in TH neurons 
OGG1 (Shimura-Miura et al. 1999) SN 
↑ total and mitochondrial 
levels  
Osteopontin (Maetzler et al. 2007) SN ↑ levels 
Osteopontin (Iczkiewicz et al. 2006) SN ↓ nb of positive cells 
PARP (Soós et al. 2004) SN ↑ levels in TH nuclei 
Peroxidase  (Ambani et al. 1975) SN, Str ↓ activity 
Peroxiredoxin 2 
(phosphorylated at 
T89) 
(Qu et al. 2007) SN ↑ levels in TH neurons 
Peroxiredoxin 2 (S-
nytrosylated) 
(Fang et al. 2007) SN ↑ levels 
Peroxiredoxin 3 
(phosphorylated) 
(Angeles et al. 2011) Ca, Cx ↑ levels 
Selenoprotein P (Bellinger et al. 2012) SN 
↓ total but ↑ levels in TH 
neuron 
Sestrin-2 (Zhou et al. 2013) SN ↑ levels 
SOD (Marttila et al. 1988) 
NBM, SN, Th, 
Tp Cx 
↑ activity 
SOD (Marttila et al. 1988) 
Ag, Ca, Cb, 
GP, Pu 
= levels 
SOD (Mythri et al. 2011),(Marttila et al. 1988) Ca, Fr Cx = activity 
SOD (Mythri et al. 2011) Pu ↓ activity 
SOD (cytosolic) (Radunović et al. 1997) Cx = activity 
SOD (mitochondrial) (Radunović et al. 1997) Cx ↑ activity 
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SOD (Mn) (Shimoda-Matsubayashi et al. 1997) Fr Cx, Pu, SN = activity 
SOD (Mn) (Navarro et al. 2009) Frontal cortex ↑ levels 
SOD1 (Choi et al. 2005b) Cg Cx ↑ levels 
SOD2 (Ferrer et al. 2007) SN ↑ levels 
Thioredoxin (Reynolds et al. 2008) SN = levels 
Total proteins 
(carbonylated)  
Fr Cx = levels 
Total proteins 
(carbonylated) 
(Alam et al. 1997) 
Ca, Cb, Fr Cx, 
GP, Nacc, Pu, 
SN 
↑ levels 
Total proteins 
(carbonylated) 
(Aksenova et al. 1999) Fr Cx = levels 
Total proteins 
(oxidized) 
(Mythri et al. 2011),(Choi et al. 2005b) Ca, Cg Cx ↑ levels 
Total proteins 
(oxidized) 
(Mythri et al. 2011) Fr Cx, Pu = levels 
Total proteins 
(nitrosylated) 
(Mythri et al. 2011) Ca, Fr Cx, Pu = levels 
TTRAP (cytoplasmic) (Vilotti et al. 2012) SN ↑ in TH neurons 
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Table 6. Changes in ubiquitin proteasome system, lysosomal and autophagy proteins observed in 
the human parkinsonian brain. Legend: see Table 1. 
 
Protein Ref Structure Observation in PD 
Ubiquitin proteasome system 
19S proteasome (Wills et al. 2010) Fr Gy, Str = levels 
20S proteasome (Wills et al. 2010) Fr Gy, Str ↓ levels 
20S proteasome (Chu et al. 2009) SN ↓ levels in neurons 
20S proteasome (α subunit) (McNaught et al. 2003) SN ↓ levels 
20S proteasome (α6 subunit) (Nakamura et al. 2006) Str 
↑ levels and nuclear 
localization 
20S proteasome (α6 subunit) (Nakamura et al. 2006) SN ↑ levels 
20S proteasome  (McNaught and Jenner 2001) SN ↓ activity 
20S proteasome  (McNaught and Jenner 2001) 
Cb, Fr Cx, Hp, 
Po, Str 
= activity 
20S/26S proteasome (McNaught and Jenner 2001) SN ↓ activity 
20S (α4 subunit) (Bukhatwa et al. 2010) SN 
↓ nb of expressing 
TH neurons 
20S (α6 subunit) (Bukhatwa et al. 2010) SN 
↓ nb of expressing 
TH neurons 
20S (β3 subunit) (Bukhatwa et al. 2010) SN = levels 
20S (β5 subunit) (Bukhatwa et al. 2010) SN = levels 
26S proteasome (Wills et al. 2010) Str = activity 
26S proteasome (Wills et al. 2010) Fr Gy ↓ activity 
26S/20S proteasome (α subunit) (McNaught et al. 2003) Fr Cx, Str = levels 
26S/20S proteasome (α subunit) (McNaught et al. 2003) SN ↓ levels 
26S/20S proteasome (β subunit) (McNaught et al. 2003) Fr Cx, SN, Str = levels 
Nedd4 (Tofaris et al. 2011) SN 
↑ cytoplasmic levels 
in TH neurons 
PA28 (McNaught et al. 2003) Fr Cx ↓ levels 
PA28 (McNaught et al. 2003) SN, Str = levels 
PA700 (McNaught et al. 2003) Fr Cx, SN, Str ↑ levels 
SKP1A (Mandel et al. 2007) SN ↓ levels 
TRIM9 (Tanji et al. 2010) SN ↓ levels 
Ubiquitinated proteins (Lonskaya et al. 2013) Str ↑ levels 
USP9X (Rott et al. 2011) SN ↓ levels 
Lysosome and autophagy 
Beclin 1 (Murphy et al. 2014) Cg Cx ↓ levels 
Beclin 1 (Miki et al. 2015) SN ↑ levels 
Beclin 1 (caspase-cleaved) (Rohn and Catlin 2011) SN ↑ levels 
Beclin1 (phosphorylated) (Miki et al. 2015) SN = levels 
Cathepsin A (Murphy et al. 2014) Cg Cx ↑ levels 
cathepsin B (Mantle et al. 1995) Fr Cx = levels 
Cathepsin D (Murphy et al. 2014) Cg Cx ↑ levels 
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Cathepsin D (Chu et al. 2009) SNc ↓ levels in neurons 
cathepsin D (Mantle et al. 1995) Fr Cx = levels 
cathepsin H (Mantle et al. 1995) Fr Cx = levels 
cathepsin L (Mantle et al. 1995) Fr Cx = levels 
Dipeptidyl aminopeptidase I (Mantle et al. 1996) Fr Cx = activity 
Dipeptidyl aminopeptidase II (Mantle et al. 1996) Fr Cx ↓ activity 
Glucocerebrosidase (Murphy et al. 2014) Cg Cx ↓ levels 
Glucocerebrosidase (Gegg et al. 2012) Crb 
↓ levels and 
activity 
Glucocerebrosidase (Gegg et al. 2012) SN 
↓ levels and 
activity 
Glucocerebrosidase (Gegg et al. 2012) Ag, Fr Cx, Pu = levels 
Hsc70 
(Alvarez-Erviti et al. 
2010),(Mandel et al. 2009) 
Ag, SN ↓ levels 
HSP73 (Chu et al. 2009) SN ↓ levels in neurons 
LAMP1 (Dehay et al. 2010) SN ↓ levels 
LAMP1 (Chu et al. 2009) SN ↓ levels in neurons 
LAMP2 
(Alvarez-Erviti et al. 
2010),(Murphy et al. 2014) 
Ag, Cg Cx, SN ↓ levels 
LC3II (Dehay et al. 2010) SN ↑ levels 
LIMP-2 (Rothaug et al. 2014) SN ↑ levels 
LMX1B (Laguna et al. 2015) SN 
↓ levels in TH 
neurons 
MEF2D (She et al. 2011) Str ↑ levels 
P-type ATPase (ATP13A2) (Dehay et al. 2012) SN ↓ levels 
P-type ATPase (ATP13A2) (Ramonet et al. 2012) Cx, Str ↑ levels 
TFEB (Decressac et al. 2013) SN 
↓ nuclear levels in 
TH neurons 
ULK1 (UNC-51-like kinase 1) (Miki et al. 2015) SN = levels 
ULK2 (UNC-51-like kinase 2) (Miki et al. 2015) SN = levels 
VPS34 (Miki et al. 2015) SN = levels 
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Table 7. Changes in apoptosis-related proteins observed in the human parkinsonian brain. 
Legend: see Table 1. 
Protein Ref Structure Effect 
Apoptosis 
AIMP2 (Lee et al. 2013) SN ↑ levels 
Apaf-1 (Kawamoto et al. 2014) SN ↑ levels in TH neurons 
Apaf-1 (Kawamoto et al. 2014) LC ↑ levels 
Bax (Tatton 2000),(Hartmann et al. 2001a) SN ↑ levels in TH neurons  
Bcl-2 (Letters et al. 1996),(Marshall et al. 1997) Ca, GP, Pu, SN ↑ levels 
Bcl-2 (Letters et al. 1996),(Marshall et al. 1997) Cb Cx, Cx = levels 
Bid/tBid (Jiang et al. 2012) Tp Cx 
↑ total and 
mitochondrial levels  
Caspase-1 (Mogi et al. 2000) SN ↑ activity 
Caspase-1 (Mogi et al. 2000) Ca, Cb, Fr Cx, Pu = activity 
Caspase-3 (Hartmann et al. 2000) SN 
↓ nb of expressing TH 
neurons 
Caspase-3 (Jiang et al. 2012) Tp Cx 
↑ total and 
mitochondrial levels 
Caspase-3 (Tatton 2000),(Mogi et al. 2000) SN 
↑ levels in TH neurons 
and activity 
Caspase-3 (Mogi et al. 2000) Ca, Cb, Fr Cx, Pu = activity 
Caspase-3 
(cleaved) 
(Jiang et al. 2012) Tp Cx 
↑ total and 
mitochondrial levels 
Caspase-3 
(cleaved) 
(Tatton 2000) SN ↑ levels in TH neurons 
Caspase-8 
(activated) 
(Viswanath et al. 2001) SN ↑ levels in TH neurons 
Caspase-8 
(activated) 
(Hartmann et al. 2001b) SN 
↑ nb of TH expressing 
neurons 
Caspase-9 (Kawamoto et al. 2014) SN ↑ levels in TH neurons 
Caspase-9 (Kawamoto et al. 2014) LC ↑ levels 
Caspase-9 
(activated) 
(Viswanath et al. 2001) SN ↑ levels in TH neurons 
Caspase-9 
(cleaved) 
(Kawamoto et al. 2014) SN ↑ levels in TH neurons 
Caspase-9 
(cleaved) 
(Kawamoto et al. 2014) LC ↑ levels 
Cytochrome c (Kawamoto et al. 2014) SN ↑ levels in TH neurons 
Cytochrome c (Kawamoto et al. 2014) LC ↑ levels 
Cytochrome c (Jiang et al. 2012) Tp Cx 
↑ total and ↓ 
mitochondrial levels 
Endonuclease G (Büttner et al. 2013) SN 
↑ nuclear localization 
in TH neurons 
FADD (Hartmann et al. 2002) SN 
↓ nb of expressing 
neurons 
Fas (Ferrer et al. 2000) SN ↓ levels  
Fas (soluble) (Mogi et al. 1996a) Ca, Pu ↑ levels 
Fas (soluble) (Mogi et al. 1996a) Cb Cx = levels 
Fas-associated 
factor 1 
(Betarbet et al. 2008) Fr Cx ↑ levels 
FasL (Ferrer et al. 2000) SN ↓ levels in TH neurons 
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FasL (Ferrer et al. 2000) SN 
↑ levels in reactive 
astrocytes 
p53 (Sunico et al. 2013),(Mogi et al. 2007) Ca, Tp Cx ↑ levels 
p53 (Mogi et al. 2007) Cb, Fr Cx, Pu, SN = levels 
p53 
(phosphorylated 
at S15) 
(Camins et al. 2010) Cg Gy ↑ levels 
PAR polymer (Lee et al. 2013) SN ↑ levels 
Par-4 (Moos and Jensen 2004) SN = levels 
TNFR1 (p55) (Jiang et al. 2012),(Mogi et al. 2000) SN, Tp Cx ↑ levels 
TNFR1 (p55) (Mogi et al. 2000) Ca, Cb, Fr Cx, Pu = levels 
TRADD (Jiang et al. 2012) Tp Cx ↑ levels 
    
    
Cell cycle re-entry 
Cdk5 (Alvira et al. 2008) Cg Cx ↑ levels 
Cdk5 (Rubio de la Torre et al. 2009) Ca, Cb, Cx = levels  
Cyclin D1 (Camins et al. 2010) Cg Cx ↑ levels 
E2F-1 (Alvira et al. 2008) Cg Cx ↑ levels 
E2F-1 (Höglinger et al. 2004) SN ↑ levels in TH neurons 
p25 
(Rubio de la Torre et al. 2009),(Alvira et al. 
2008) 
Ca, Cg Cx ↑ levels 
p25 (Rubio de la Torre et al. 2009) Cb, Cx = levels 
p35 (Rubio de la Torre et al. 2009) Ca, Cb, Cx = levels 
PCNA (Höglinger et al. 2004) SN ↑ levels in TH neurons 
pRb (Jordan-Sciutto et al. 2003) Fr Cx, Hp, SN ↑ levels 
pRb 
(phosphorylated) 
(Jordan-Sciutto et al. 2003) Fr Cx, Hp, SN ↑ nuclear levels 
Endoplasmic reticulum stress 
EIF2α 
(phosphorylated 
at S51) 
(Hoozemans et al. 2007) SN 
↑ nb of expressing TH 
neurons 
HERP (Slodzinski et al. 2009) SN ↑ levels 
IRE1α (Hoozemans et al. 2012) SN 
↑ nb of expressing TH 
neurons 
PERK 
(phosphorylated 
at Thr981) 
(Hoozemans et al. 2007) SN 
↑ nb of expressing TH 
neurons 
PKR 
(phosphorylated 
at Thr446) 
(Bando et al. 2005) Hp ↑ nuclear levels 
Transcription factors and transduction pathways 
14-3-3 (phosphorylated at 
S58)  
(Slone et al. 2015) Tp Cx ↓ membrane levels 
14-3-3 (total pan) (Slone et al. 2015) Tp Cx = levels 
14-3-3ɵ (phosphorylated at 
S232) 
(Slone et al. 2015) Tp Cx ↑ cytoplasmic levels 
14-3-3σ (Reynolds et al. 2008) SN ↑ levels 
Akt (phosphorylated at S473) (Timmons et al. 2009) Mb ↓ levels 
Akt (phosphorylated at S473) (Malagelada et al. 2008) SN ↓ levels in TH neurons 
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Akt (phosphorylated at T308) (Malagelada et al. 2008) SN ↓ levels in TH neurons 
Akt (total) (Timmons et al. 2009) Mb ↓ levels 
ASK1 (phosphorylated) (Hu et al. 2011) SN 
↑ nb of expressing TH 
neurons 
c-jun (Hunot et al. 2004) SN ↑ levels in TH neurons 
c-Myc (Ferrer and Blanco 2000) SN = levels in TH neurons 
c-Myc (Ferrer and Blanco 2000) SN 
↑ nb of expressing 
astrocytes 
CREB (phosphorylated) (Kurup et al. 2015) Str ↓ levels 
CREB 
(phosphorylated)/CREB 
(Price et al. 2010) Fr Cx 
↑ nuclear and ↓ 
cytoplasmic levels 
Elk (phosphorylated)/Elk (Price et al. 2010) Fr Cx = ratio 
ERK (phosphorylated)/ERK (Price et al. 2010) Fr Cx ↑ ratio 
ERK1/2 (phosphorylated) (Kurup et al. 2015) Str ↓ levels 
GSK3β (phosphorylated at 
Y216) 
(Wills et al. 2010) Str ↑ levels 
GSK3β (phosphorylated at 
Y216) 
(Wills et al. 2010) Fr Cx = levels 
Itch (Pranski et al. 2013) Cx, SN = levels 
JNK (phosphorylated) (Hu et al. 2011) SN 
↑ nb of expressing TH 
neurons 
MEF2D (Gao et al. 2014) Str ↓ mitochondrial levels 
MEF2D (Chu et al. 2011) SN ↓ levels 
MEF2D (Chu et al. 2011) SN ↓ levels in TH neurons 
NFATc4 (Caraveo et al. 2014) Fr Cx, Hp, SN ↑ nuclear levels 
NF-κB (nuclear) 
(Soós et al. 2004),(Hunot et al. 
1997) 
SN ↑ levels in TH neurons  
NF-κB (p50), cytosol (Reynolds et al. 2008) SN 
↑ cytosolic and nuclear 
levels 
NF-κB (p65) 
(Reynolds et al. 2008),(Ghosh et 
al. 2009) 
Mb 
↑ total, cytosolic and 
nuclear levels 
NF-κB (phosphorylated at 
S536) 
(Reynolds et al. 2008) SN ↑ levels 
NF-κB (total) (Mogi et al. 2007) Ca, Pu, SN ↑ levels 
n-myc (Ferrer and Blanco 2000) SN = levels in TH neurons 
n-myc (Ferrer and Blanco 2000) SN 
↑ nb of expressing 
astrocytes 
Nurr1 (Chu et al. 2006) SN ↓ levels in TH neurons 
Nurr1 (Chu et al. 2006) SN 
↓ nb of expressing TH 
neurons 
p38 (phosphorylated) (Hu et al. 2011) SN 
↑ nb of expressing TH 
neurons 
p53 
(Sunico et al. 2013),(Mogi et al. 
2007) 
Ca, Tp Cx ↑ levels 
p53 (Mogi et al. 2007) Cb, Fr Cx, Pu, SN = levels 
p53 (phosphorylated at S15) (Camins et al. 2010) Cg Gy ↑ levels 
PGC-1α 
(Eschbach et al. 2015; Shin et al. 
2011) 
SN, Str ↓ levels 
PTEN (S-nytrosylated) (Choi et al. 2014) Fr Cx ↓ ratio / total DJ-1 
RNF11 (Pranski et al. 2013) Cx, SN ↓ levels 
RPT801 (REDD1) (Malagelada et al. 2006) SN ↑ levels in TH neurons 
Tax1BP1 (Pranski et al. 2013) Cx, SN = levels 
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Summarizing Schematic 
 
 
 
Parkinson’s is accompanied by multiple changes in the brain that are responsible of the progression of 
the disease. We describe here the molecular alterations occurring in postmortem brains and classify 
them as: Neurotransmitters and neurotrophic factors; Lewy bodies and Parkinson’s-linked genes; 
Transition metals, calcium and calcium-binding proteins; Inflammation; Mitochondrial abnormalities 
and oxidative stress; Abnormal protein removal and degradation; Apoptosis and transduction 
pathways. 
